0001144204-16-102291.txt : 20160516 0001144204-16-102291.hdr.sgml : 20160516 20160516123133 ACCESSION NUMBER: 0001144204-16-102291 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AntriaBio, Inc. CENTRAL INDEX KEY: 0001509261 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273440894 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54495 FILM NUMBER: 161652121 BUSINESS ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 BUSINESS PHONE: 650-847-1919 MAIL ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 FORMER COMPANY: FORMER CONFORMED NAME: FITS MY STYLE INC DATE OF NAME CHANGE: 20110104 10-Q 1 v438591_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2016
OR
¨		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-54495

ANTRIABIO, INC

(Exact Name of Registrant as Specified in its Charter)

Delaware		27-3440894
(State of other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1450 Infinite Drive, Louisville, Colorado		80027
(Address of Principal Executive Offices)		(Zip Code)

(303) 222-2128

(Registrant’s Telephone Number, including Area Code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the Registrant is ¨ a large accelerated filer, ¨ an accelerated file, ¨ a non-accelerated filer, or x a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)
¨ Yes x No

Number of shares of issuer’s common stock outstanding as of May 16, 2016: 24,338,219

TABLE OF CONTENTS

		Page

PART I - FINANCIAL INFORMATION		2

ITEM 1. FINANCIAL STATEMENTS (unaudited)		2

Consolidated Balance Sheets – March 31, 2016 and June 30, 2015		2

Consolidated Statements of Operations - Three and nine months ended March 31, 2016 and 2015		3

Consolidated Statements of Stockholders’ Equity - From June 30, 2014 to March 31, 2016		4

Consolidated Statements of Cash Flows - Nine months ended March 31, 2016 and 2015		5

Notes to Consolidated Financial Statements		6

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		16
ITEM 3. QUALITATIVE AND QUANTITATIVE DISCUSSION ABOUT MARKET RISK		20
ITEM 4. CONTROLS AND PROCEDURES		20

PART II – OTHER INFORMATION		20

ITEM 1. LEGAL PROCEEDINGS		20
ITEM 1A. RISK FACTORS		20
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		20
ITEM 3. DEFAULTS UPON SENIOR SECURITIES		21
ITEM 4. MINE SAFETY DISCLOSURE		21
ITEM 5. OTHER INFORMATION		21
ITEM 6. EXHIBITS		21

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “may,” “should,” “plan,” “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:

•

projected operating or financial results, including anticipated cash flows used in operations;

•

expectations regarding capital expenditures, research and development expense and other payments;

•

our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;

•

our ability to obtain regulatory approvals for our pharmaceutical drugs and diagnostics; and

•

our future dependence on third party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval, and our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements.

Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, among others:

•

the loss of key management personnel or sponsored research partners on whom we depend;

•

the progress and results of clinical trials for our product candidates;

•

our ability to navigate the regulatory approval process in the U.S. and other countries, and our success in obtaining required regulatory approvals for our product candidates;

•

commercial developments for products that compete with our product candidates;

•

the actual and perceived effectiveness of our product candidates, and how those product candidates compare to competitive products;

•

the strength of our intellectual property protection, and our success in avoiding infringing the intellectual property rights of others;

•

adverse developments in our research and development activities;

•

potential liability if our product candidates cause illness, injury or death, or adverse publicity from any such events;

•

our ability to operate our business efficiently, manage capital expenditures and costs (including general and administrative expenses) and obtain financing when required;

•

our expectations with respect to our acquisition activity.

In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Quarterly Report of Form 10-Q are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q, except as otherwise required by applicable law.

AntriaBio, Inc.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

Consolidated Balance Sheets

	March 31, 2016			June 30, 2015
	(Unaudited)
Assets

Current assets
Cash	$	1,746,022		$	5,278,706
Restricted cash		-			450,167
Other current assets		294,278			387,511
Total current assets		2,040,300			6,116,384

Non-current assets
Fixed assets, net		6,134,613			4,524,912
Intangibile assets, net		53,437			58,906
Deposit		562,500			563,000
Total non-current assets		6,750,550			5,146,818

Total Assets	$	8,790,850		$	11,263,202

Liabilities, Series A Convertible Preferred Stock and Stockholders' Equity

Current liabilities:
Accounts payable and accrued expenses	$	2,168,973		$	1,408,399
Convertible notes payable		60,000			60,000
Deferred lease liability, current portion		116,952			98,671
Lease payable, current portion		46,946			93,852
Interest payable		14,579			13,079
Warrant derivative liability		11,679			31,777
Total current liabilities		2,419,129			1,705,778

Non-current liabilities:
Deferred lease liability, less current portion		431,341			480,490
Lease payable, less current portion		-			23,127
Total non-current liabilities		431,341			503,617

Total Liabilities		2,850,470			2,209,395

Commitments and Contingencies (Note 11)

Series A Convertible Preferred Stock - subject to redemption,
$0.01 par value, $1.95 redemption value; 15,000,000 authorized;
2,769,422 and no shares issued and outstanding,
March 31, 2016 and June 30, 2015, respectively		4,821,802			-

Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized;
none issued and outstanding		-			-
Common stock, $0.001 par value, 200,000,000 shares authorized;
24,338,219 and 24,338,219 shares issued and outstanding,
March 31, 2016 and June 30, 2015		24,341			24,341
Additional paid-in capital		41,268,207			38,138,754
Accumulated deficit		(40,173,970	)		(29,109,288	)
Total stockholders' equity		1,118,578			9,053,807

Total Liabilities, Series A Convertible Preferred Stock and Stockholders' Equity	$	8,790,850		$	11,263,202

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Consolidated Statements of Operations

	Three Months						Nine Months
	Ended March 31,						Ended March 31,
	2016			2015			2016			2015
	(Unaudited)						(Unaudited)
Operating expenses
Research and development
Compensation and benefits	$	1,180,350		$	628,252		$	3,187,751		$	1,306,806
Consultants and outside costs		265,470			166,472			869,750			425,891
Material manufacturing costs		461,599			296,385			1,837,110			871,308
Facilities and other costs		402,770			199,686			907,721			365,511
		2,310,189			1,290,795			6,802,332			2,969,516

General and administrative
Consulting fees		-			33,000			-			349,633
Compensation and benefits		907,626			780,500			3,025,476			2,828,032
Professional fees		106,791			72,270			344,964			362,339
Investor relations		88,138			36,602			202,458			468,047
General and administrative		302,731			87,033			706,380			626,777
		1,405,286			1,009,405			4,279,278			4,634,828

Total operating expenses		3,715,475			2,300,200			11,081,610			7,604,344

Loss from operations		(3,715,475	)		(2,300,200	)		(11,081,610	)		(7,604,344	)

Other income (expense)
Interest income		1			1,093			965			4,062
Interest expense		(1,143	)		(2,086	)		(4,135	)		(4,885	)
Derivative gains (losses)		5,782			(871,447	)		20,098			(717,733	)
Total other income (expense)		4,640			(872,440	)		16,928			(718,556	)

Net loss	$	(3,710,835	)	$	(3,172,640	)	$	(11,064,682	)	$	(8,322,900	)

Cumulative Preferred Stock dividend		(61,279	)		-			(61,279	)		-

Net loss attributable to common stock	$	(3,772,114	)	$	(3,172,640	)	$	(11,125,961	)	$	(8,322,900	)

Net loss per common share - basic and diluted	$	(0.15	)	$	(0.14	)	$	(0.46	)	$	(0.42	)

Weighted average number of common shares outstanding - basic and diluted		24,338,219			22,542,821			24,338,219			19,840,425

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Consolidated Statements of Stockholders' Equity

From June 30, 2014 to March 31, 2016 (Unaudited)

					Additional						Total
	Common Stock, $0.001 Par Value				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity

Balance at June 30, 2014		18,091,792	$	18,092	$	24,135,563		$	(17,746,924	)	$	6,406,731

Stock-based compensation		-		-		2,846,828			-			2,846,828

Issuance of common stock for services		205,506		207		368,212			-			368,419

Fair value of warrants issued		-		-		6,026,070			-			6,026,070

Issuance of common stock, net of issuance costs of $3,144,479		6,040,921		6,042		4,762,081			-			4,768,123

Net loss for the year ended June 30, 2015		-		-		-			(11,362,364	)		(11,362,364	)

Balance at June 30, 2015		24,338,219	$	24,341	$	38,138,754		$	(29,109,288	)	$	9,053,807

Stock-based compensation (Unaudited)		-		-		2,877,628			-			2,877,628

Fair value of warrants issued (Unaudited)		-		-		313,104			-			313,104

Dividends on Series A Preferred Stock (Unaudited)		-		-		(61,279	)		-			(61,279	)

Net loss for the nine months ended March 31, 2016 (Unaudited)		-		-		-			(11,064,682	)		(11,064,682	)

Balance at March 31, 2016 (Unaudited)		24,338,219	$	24,341	$	41,268,207		$	(40,173,970	)	$	1,118,578

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months
	Ended March 31,
	2016			2015

CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$	(11,064,682	)	$	(8,322,900	)
Amortization of intangible asset		5,469			3,432
Depreciation expense		476,941			91,021
Stock-based compensation expense		2,877,628			1,864,226
Stock issued for services		-			298,418
Derivative (gains) losses		(20,098	)		717,733
Warrant expense		62,941			84,558
Forgiveness of accounts payable and accrued expenses - related party		-			132,339
Changes in operating assets and liabilities:
(Decrease) increase in other assets		(93,767	)		105,577
Increase in accounts payable and accrued expenses		448,345			380,727
Decrease in accounts payable and accrued expenses - related party		-			(529,394	)
Increase in interest payable		1,500			1,500
(Decrease) increase in deferred lease liability		(30,868	)		57,017
Net Cash Used In Operating Activities		(7,336,591	)		(5,115,746	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(1,774,413	)		(874,960	)
Acquisition of intangibles		-			(55,000	)
Return of security deposit		187,500			-
Decrease (increase) in restricted cash		450,167			(450,055	)
Net Cash Used In Investing Activities		(1,136,746	)		(1,380,015	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on lease payable		(70,033	)		(45,019	)
Proceeds from issuance of equity financing		-			9,761,070
Proceeds from issuance of preferred stock		5,347,615			-
Payment of placement agent compensation and issuance costs		(336,929	)		(930,106	)
Net Cash Provided by Financing Activities		4,940,653			8,785,945

Net (decrease) increase in cash		(3,532,684	)		2,290,184

Cash - Beginning of Period		5,278,706			5,934,534

Cash - End of Period	$	1,746,022		$	8,224,718

SUPPLEMENTARY CASH FLOW INFORMATION:
Cash Paid During the Period for:
Taxes	$	-		$	-
Interest	$	-		$	-

Non-Cash Transactions:
Fixed assets acquired through lease payable	$	-		$	184,877
Fixed assets acquired through tenant improvements	$	-		$	511,616
Warrant value recorded as issuance costs	$	250,163		$	1,671,618
Fixed assets included in accounts payable and accrued expenses	$	312,229		$	484,716
Warrant derivative liability reclassified as equity	$	-		$	2,217,605
Series A Preferred Stock dividend paid in stock	$	61,279		$	-

See accompanying notes to consolidated financial statements

AntriaBio, Inc.

Notes to Consolidated Financial Statements
March 31, 2016
(Unaudited)

Note 1 Nature of Operations

These financial statements represent the consolidated financial statements of AntriaBio, Inc. (“AntriaBio”), formerly known as Fits My Style, Inc., and its wholly owned operating subsidiary, AntriaBio Delaware, Inc. (“Antria Delaware”). AntriaBio and Antria Delaware are collectively referred to herein as the “Company”.

Note 2 Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed on September 28, 2015, which contains the audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the year ended June 30, 2015.

Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2016 are not necessarily indicative of results for the full fiscal year.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.

Risks and Uncertainties

The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters.

Restricted Cash

Restricted cash consisted of cash held in a joint account with our general contractor until the completion of the construction in progress. As the construction process was completed as of December 31, 2015, the restricted cash was released and used to pay the final invoices to the general contractor.

Research and Development Costs

Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. These costs relate to research and development costs without an allocation of general and administrative expenses.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices for identical assets and liabilities in active markets;

Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The carrying amounts of financial instruments including cash, restricted cash, accounts payable and accrued expenses, and convertible notes payable approximated fair value as of March 31, 2016 and June 30, 2015 due to the relatively short maturity of the respective instruments.

The warrant derivative liability recorded as of March 31, 2016 and June 30, 2015 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value measurement with the entire change in the balance recorded through earnings. See significant assumptions in Note 9. The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:

Balance as of June 30, 2015	$	(31,777	)
Total unrealized gains (losses):
Included in earnings		20,098
Balance as of March 31, 2016	$	(11,679	)

Recent Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"), which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform assessments of an entity's ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform the going concern assessment under ASU 2014-15 beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition, results of operations or disclosures.

In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20), which eliminates the concept of extraordinary items. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. The new guidance is to be applied prospectively but may also be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We expect to adopt the provisions of this new guidance beginning with the year ended June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.

In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes, which is intended to improve how deferred taxes are classified on organizations’ balance sheets by eliminating the current requirement for organizations to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, organizations will now be required to classify all deferred tax assets and liabilities as noncurrent. The changes are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We expect to adopt the provisions of this new guidance on July 1, 2016. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 will be effective for us starting on July 1, 2018, and early adoption is not permitted. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09. Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The update will affect all entities that issue share-based payment awards to their employees and is effective for annual periods beginning after December 15, 2016 for public entities. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.

Note 3 Going Concern

As reflected in the accompanying financial statements, the Company has a net loss of $11,064,682 and net cash used in operations of $7,336,591 for the nine months ended March 31, 2016, and working capital deficit of $378,829 and stockholders’ equity of $1,118,578 with an accumulated deficit of $40,173,970 at March 31, 2016. In addition, the Company is in the preclinical stage and has not yet generated any revenues. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on Management's plans, which include continuing to raise capital through issuances of common and preferred stock.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the satisfaction of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 Fixed Assets

The following is a summary of fixed assets and accumulated depreciation:

	Useful
	Life	March 31, 2016			June 30, 2015
Furniture and fixtures	5 - 7 years	$	62,730		$	55,330
Lab equipment	3 - 15 years		3,378,355			889,671
Lab equipment (not yet placed in service)	3 - 15 years		113,965			1,371,441
Leasehold improvements	3 - 7 years		3,191,792			29,296
Construction in process	-		-			2,315,803
			6,746,842			4,661,541
Less: accumulated depreciation and amortization			(612,229	)		(136,629	)
		$	6,134,613		$	4,524,912

The construction in process was completed as of December 31, 2015 and the balance was recorded into leasehold improvements at which time it began depreciating over the remaining life of the lease. Depreciation expense was $256,404 and $33,113 for the three months ended March 31, 2016 and 2015, respectively, and was $476,941 and $91,021 for the nine months ended March 31, 2016 and 2015, respectively.

Note 5 Related Party Transactions

During the three and nine months ended March 31, 2016, there were no related party transactions. During the three and nine months ended March 31, 2015, the Company incurred consulting expenses of $33,000 and $99,000, respectively, for services performed by related parties of the Company and included in the statements of operations.

Note 6 Convertible Notes Payable

From 2010 to 2012, the Company issued several series of convertible promissory notes for which principal and interest were due between six months and two years after issuance. The convertible notes allowed investors to convert their shares into common stock at the time of certain qualifying events with some of the notes also issuing warrants at the time of conversion.

During 2014, the Company sent letters to the holders of the 2010, 2011 and 2012 notes requesting amendment of their convertible notes payable. The convertible notes payable were amended to: (i) fix the conversion price of the notes into common stock at $1.50 per share, (ii) require mandatory conversion of principal and interest, and (iii) change the definition of a qualified financing to an equity financing of at least three million dollars. Note holders of $3,032,500 of the convertible notes payable balances outstanding have signed and returned the amendment letter. Based on the fixed conversion price, the intrinsic value of the beneficial conversion feature of $653,000 was calculated and recorded as a discount to the notes payable. As of June 30, 2014, $653,000 of the debt discount has been amortized into interest expense as these all amortized as part of the conversion.

2013 Notes – In December 2013 and January 2014, the Company issued $2,703,000 of 8% convertible promissory notes payable for which principal and interest is due six months after the date of issuance. Pursuant to the note agreements, if the Company issues equity securities in a transaction resulting in gross proceeds of at least $3,000,000, the promissory note and accrued interest will automatically convert to common stock at a conversion price of $1.26 per share. The notes also allow the investor to convert at any time prior to maturity at $1.26 per share at their option. With the promissory note, the investor will also receive a warrant to purchase common stock equal to one-half of the principal amount of the promissory note. The warrant will have an exercise price of $1.89 per share and will be exercisable for three years from date of issuance.

The value of the proceeds of the notes was allocated to the warrants as discussed in Note 9 and the remaining balance was allocated to the beneficial conversion feature as the intrinsic value of the beneficial conversion feature is greater than the remaining value of the notes. The discount on the notes is being amortized into interest expense over the remaining life of the notes.

On March 31, 2014, the Company closed on an equity transaction which qualified as a “qualified financing” as such the $2,703,000 in 2013 Notes and the accrued interest was converted into 2,186,838 shares of our common stock. The Company also converted $4,275,172 of the 2010, 2011 and 2012 Notes and accrued interest into 3,111,126 shares of our common stock. The remaining balance of any debt discounts on the notes converted was recorded into interest expense at the time of the conversion.

As of March 31, 2016 and June 30, 2015, the convertible notes outstanding balance was $60,000 and $60,000, respectively. As of March 31, 2016, all of the outstanding convertible notes have matured and payments were due. The convertible notes which have not been repaid or converted continue to accrue interest at a rate of 8%.

Note 7 Series A Convertible Preferred Stock

On December 7, 2015, the Board of Directors authorized 15,000,000 shares of Series A Convertible Preferred Stock (“Series A Stock”). The Series A Stock has a conversion feature at the option of the holder that can be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also have a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Company’s listing to NASDAQ Stockmarket or the NYSE MKT and the Company’s common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stock’s conversion price is subject to weighted average anti-dilution protection, as defined, and is subject to adjustments for stock splits, dividends, and similar events. The Series A Stock is redeemable ten years after the issuance date or upon a liquidation event, as defined, which includes a change in control and therefore recorded before Stockholders’ Equity on the consolidated balance sheet. The Series A Stock is entitled to an annual dividend of 6% based on the original issuance price, compounded quarterly. The dividend is cumulative and will be paid in shares of Series A Stock. The accrued dividends are payable upon redemption or conversion. The Series A Stock has voting rights equal to common stockholders as if the Series A Stock converted into common stock on the record date of the vote. The Series A Stock also has liquidation preferences over other shareholders. As of March 31, 2016, the liquidation preference was $1.95 per share.

On December 10, 2015, the Company closed an initial offering of its Series A Stock with an offering price of $1.95 per share. The Company issued 1,025,699 shares and received net proceeds of $1,803,548 after the placement agent compensation and issuance costs paid of $105,715 and a warrant with a fair value of $90,852 recorded as issuance costs. On March 2, 2016, the Company closed a second offering of its Series A Stock with an offering price of $1.95 per share. The Company issued 1,716,487 shares and received net proceeds of $2,956,975 after the placement agent compensation and issuance costs paid of $231,214 and a warrant with a fair value of $159,311 recorded as issuance costs. The issuance costs are being accreted over the ten-year life of the Series A Stock of which $8,169 was accreted during the three months ended March 31, 2016.

On March 31, 2016, the Company declared and issued 27,236 shares of Series A Stock as dividends on the current outstanding shares of Series A Stock.

On April 12, 2016, the Company completed an additional close of its Series A Stock with an offering price of $1.95 per share. The Company issued 512,820 shares and received gross proceeds of $1 million.

Note 8 Shareholders’ Equity

On March 31, 2014, the Company entered into a services agreement whereby the Company receives assistance with investor relations relating to digital strategy, website and investor materials, market awareness and other services. The compensation for these services was up to 500,000 shares of common stock to be issued over a twelve-month period. For the year ended June 30, 2015, 166,668 shares of common stock were issued under the agreement and $296,669 was recorded as investor relations expense during the year ended June 30, 2015. On November 1, 2014 the agreement was terminated and no additional compensation was paid.

During 2015, the Company completed two private placement transactions in which the Company issued 6,040,921 units to accredited investors. Each unit consists of one share of our common stock and one common share purchase warrant. Each warrant entitles the holder to purchase one share of common stock at a price of $2.50 per share and the warrant will expire 36 months following the issuance. The Company received net proceeds of $10.1 million after the placement agent compensation and issuance costs paid of $1,071,568 and $2,072,911 of warrant expense recorded as issuance costs. The Company also issued 37,838 shares of common stock for services in assisting in the private placement and $70,000 had been recorded in additional paid in capital as issuance costs.

The Company has not declared or paid any dividends or returned any capital to common stock shareholders as of March 31, 2016.

Note 9 Stock-Based Compensation

Options - AntriaBio adopted individual stock option plans in January 2013 for four officers and/or directors of the Company. The stock option plans granted 1,500,000 option shares with an exercise price of $4.50 per share. Options to purchase 819,445 shares vested immediately, options to purchase 541,667 shares vest monthly over 3 years and 138,888 shares vest on May 31, 2013. In June 2013, AntriaBio adopted individual stock option plans for two consultants of the Company. The stock option plans granted 8,334 shares with an exercise price of $4.50 per share and had fully vested as of June 30, 2015.

On March 26, 2014, the Company adopted the AntriaBio, Inc. 2014 Stock and Incentive Plan which allows the Company to issue up to 3,750,000 of common stock in the form of stock options, incentive options or common stock. As of March 31, 2016, the Company granted 3,295,000 of these shares to current employees and directors of the Company. The options have an exercise price from $1.29 to $3.44 per share. The options vest monthly over four years, with some options subject to a one year cliff before options begin to vest monthly.

On February 23, 2015, the Company adopted the AntriaBio, Inc. 2015 Non Qualified Stock Option Plan which allows the Company to issue up to 6,850,000 of common stock in the form of stock options. As of March 31, 2016, the Company had granted 4,162,000 of these shares to current employees and directors of the Company. The options have an exercise price of from $1.40 to $2.06 per share. The options vest monthly over 4 years with some options subject to a one year cliff before options begin to vest monthly.

AntriaBio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of peer companies. Due to the small number of option holders and all options being to officers and/or directors, AntriaBio has estimated a forfeiture rate of zero as the value of each option holder is calculated individually. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2016 using the following assumptions:

Expected volatility	100	%
Risk free interest rate	1.91	%
Expected term (years)	7
Dividend yield	0	%

Stock option activity is as follows:

				Weighted		Weighted Average
	Number of			Average		Remaining
	Options			Exercise Price		Expected Life
Outstanding, June 30, 2014		4,343,334		$	3.61		5.6
Granted		4,572,000		$	2.02
Forfeited		(212,916	)	$	3.57
Outstanding, June 30, 2015		8,702,418		$	2.78		7.1
Granted		50,000		$	1.40
Forfeited		(35,000	)	$	1.75
Outstanding, March 31, 2016		8,717,418		$	2.77		6.4

Exercisable at March 31, 2016		4,041,063		$	3.27		5.0

Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development – compensation and benefits expense of $297,925 and $917,892, respectively, and as general and administrative – compensation and benefits expense of $613,710 and $1,959,736, respectively, for the three and nine months ended March 31, 2016. The unrecognized stock-based compensation expense at March 31, 2016 is $8,599,608. AntriaBio determined the fair value as of the date of grant using the Black-Scholes option pricing method and expenses the fair value ratably over the vesting period.

Warrants- AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:

				Weighted		Weighted Average
	Number of			Average		Remaining
	Warrants			Exercise Price		Contractual Life
Outstanding, June 30, 2014		11,099,739		$	2.21		3.6
Warrants issued in private placement		6,040,921		$	2.50
Warrants issued to placement agent		1,824,489		$	2.50
Warrants issued for investor relations		111,000		$	1.63
Warrants cancelled		(59,758	)	$	2.92
Outstanding, June 30, 2015		19,016,391		$	2.33		3.0
Warrants issued for investor relations		87,000		$	1.70
Warrants issued to placement agent		271,990		$	2.39
Warrants cancelled		(30,000	)	$	3.44
Outstanding, March 31, 2016		19,345,381		$	2.32		2.3

Year Ended June 30, 2015: The Company issued warrants to purchase 6,040,921 shares of common stock at a price of $2.50 per share, exercisable through April 2018 in connection with the issuance of units in private placements. The Company issued warrants to the placement agent to purchase agent to purchase 1,824,489 shares of common stock at a price of $2.50 per share, exercisable through April 2022 in connection with the private placements that occurred from November 2014 through April 2015. The Company issued warrants to purchase 105,000 shares of common stock at a price of $1.65 per share in connection with investor relations services. The Company issued warrants to purchase 6,000 shares of common stock at a price of $1.38 per share in connection with investor relations services.

For the Nine Months Ended March 31, 2016: The Company issued warrants to purchase 9,000 shares of common stock at a price of $1.38 per share in connection with investor relations services. The Company issued warrants to purchase 18,000 shares of common stock at a price of $1.34 per share in connection with investor relations services. The Company issued warrants to purchase 60,000 shares of common stock at a price of $1.85 per share in connection with investor relations services. The Company issued warrants to the placement agents to purchase 271,990 shares of common stock at a weighted average price of $2.39 per share, exercisable through October 2023 in connection with the preferred stock offering that occurred during the nine months ended March 31, 2016.

The warrants exercisable for the 66,667 shares of common stock are accounted for under liability accounting for the shares that have vested and were recorded at their fair value on the date of issuance of $50,365 as a liability and as professional fees and investor relation expense. Warrants for 30,000 shares of the common stock were cancelled as of December 31, 2015 as the vesting events for the warrants had not occurred. The fair value as of March 31, 2016 and June 30, 2015 were $11,679 and $31,777, respectively which is reflected as a liability with the fair value adjustment recorded as derivative gains or losses on the consolidated statements of operations.

The warrants exercisable for the 4,968,482 shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $3,527,816 and the allocated fair value of $2,597,932 was recorded into additional paid-in capital. The warrants exercisable for the 1,072,439 shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $1,009,433 and the allocated fair value of $595,184 was recorded into additional paid-in capital. The warrants exercisable for the 105,000 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $80,677 and recorded as additional paid-in-capital and professional fees. The warrants exercisable for the 6,000 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $9,006 and recorded as additional paid-in-capital and professional fees.

The warrants exercisable for the 9,000 shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $11,407 and recorded as additional paid-in-capital and investor relations. The additional warrants exercisable for the 18,000 shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $17,412 and recorded as additional paid-in-capital and investor relations. The warrants exercisable for the 60,000 shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $34,122 and recorded as additional paid-in-capital and investor relations. The warrants exercisable for 271,990 shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $250,163 and recorded as additional paid-in-capital and Series A Convertible Preferred Stock as issuance costs.

The warrants exercisable for the 1,477,287 shares were accounted for under liability accounting on the date they were recorded, except for 58,914 shares which were recorded directly into equity using the Black-Scholes pricing model on February 23, 2015 at a fair value of $92,111. The warrants to purchase 1,418,373 shares had a value of $1,498,809 when originally recorded using a Lattice pricing model and $2,217,605 as of February 23, 2015 using a Black-Scholes pricing model when the warrant terms became fixed and were reclassified into equity with the fair value adjustment recorded as derivative expense on the consolidated statement of operations. The warrants exercisable for the 347,202 shares were accounted for under liability accounting on the date they were recorded, except for 247,552 shares which were recorded directly into equity using the Black-Scholes pricing model on April 6, 2015 at a fair value of $309,121. The warrants to purchase 99,650 shares had a value of $172,809 when originally recorded using a Lattice pricing model and $124,434 as of April 6, 2015 using a Black-Scholes pricing model when the warrant terms became fixed and were reclassified into equity with the fair value adjustment recorded as derivative expense on the consolidated statement of operations.

The warrants were valued using the Black-Scholes option pricing model on the date of issuance except for the warrants to purchase 1,518,387 shares which were valued using a Lattice pricing model. In order to calculate the fair value of the warrants in both models, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and warrant term. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of a peer company. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.

The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions were as follows:

Expected volatility	82% - 124%
Risk free interest rate	0.56% - 2.21%
Warrant term (years)	1 - 7.5
Dividend yield	0	%

We utilize a Lattice model to determine the fair market value of the warrants to purchase 1,418,373 shares on the day they were issued. The warrants issued resulted in a warrant derivative liability of $1,498,809 on the dates they were issued. The Lattice model accommodates the probability of exercise price adjustment features as outlined in the placement agent agreement. Under the terms of the placement agent agreement, until the final close of the private placement financing under the agreement, the exercise price per share can be reduced in proportion to the exercise price per share of warrants issued in the private placement that is lower than the exercise price per share as stated in the warrant agreement. The estimated fair value was derived using the lattice model with the following assumptions:

Expected volatility	90% - 91%
Risk free interest rate	1.89% - 1.98%
Warrant term (years)	7
Dividend yield	0	%

We utilize a Lattice model to determine the fair market value of the warrants to purchase 99,650 shares on March 31, 2015, the day they were issued. The warrants issued resulted in a warrant derivative liability of $172,809 on the date they were issued. The Lattice model accommodates the probability of exercise price adjustment features as outlined in the placement agent agreement. Under the terms of the placement agent agreement, until the final close of the private placement financing under the agreement, the exercise price per share can be reduced in proportion to the exercise price per share of warrants issued in the private placement that is lower than the exercise price per share as stated in the warrant agreement. The estimated fair value was derived using the lattice model with the following assumptions:

Expected volatility	90	%
Risk free interest rate	1.71	%
Warrant term (years)	7
Dividend yield	0	%

Note 10 Income Taxes

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items which are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.

In the nine months ended March 31, 2016, the Company did not record any income tax provision due to expected future losses and full valuation allowance on its deferred tax assets.

Note 11 Commitments and Contingencies

Lease Commitments – In May 2014, the Company entered into a lease of approximately 27,000 square feet of office, laboratory and clean room space to be leased for seventy two months. The lease requires monthly payments of $28,939 adjusted annually by approximately 3% plus triple net expenses monthly of $34,381 adjusted annually. The Company also made a security deposit of $750,000 which is held by the landlord, of which $187,500 has been returned to the Company and the remaining balance will be returned gradually over the next several years.

As of March 31, 2016, the minimum rental commitment under the lease is as follows:

Year Ending June 30,
2016 (remaining)		91,208
2017		370,252
2018		381,360
2019		392,855
2020		335,747
	$	1,571,422

In September 2014, the Company entered into an equipment lease for laboratory equipment to be leased for twenty-four months with a bargain purchase option at the end of the lease. The equipment lease has been recorded as a capital lease with monthly payments of $8,075 per month to be made.

As of March 31, 2016, minimum rental commitment under the lease is as follows:

Year Ending June 30,
2016 (remaining)	$	24,223
2017		24,223
Total rental commitments		48,446
Less: Interest payments		(1,500	)
Total lease payable		46,946
Lease payable, current portion		46,946
Lease payable, less current portion	$	-

Legal Matters - From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of March 31, 2016, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholders, is an adverse party or has a material interest adverse to our interest.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

General

This discussion and analysis should be read in conjunction with the accompanying financial statements and related notes. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.

Executive Summary

AntriaBio, is a biopharmaceutical company that develops novel, sustained release injectable therapies. We apply our proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected products that have the potential to significantly improve existing standards of care.

Our lead product candidate, AB101 is a microsphere formulation of human recombinant insulin and a biodegradable polymer that is injected subcutaneously once per week for patients with type 1 and type 2 diabetes mellitus. We believe that AB101 has the potential to provide a near peak-less, slow and uniform release of basal insulin. The current standard of care in the $11 billion basal insulin market is daily or twice a day injections.

In the quarter ended March 31, 2016, we continued the development of the AB101 program with primary goal of commencing our first clinical study in 2016. Specifically, having completed construction of our cGMP suite

in the 4^th quarter of calendar year 2015, we began testing our new equipment and refining our manufacture processes to enable the production of sterile batches of AB101 suitable for human injection. In January 2016, Michael Deperro joined the team as head of operations and he is spearheading our clinical manufacturing campaign.

It is critical that we replicate the successful GLP manufacture of AB101 in our labs in our new sterile manufacturing suite in order to facilitate the timely commencement of our first clinical study. In addition to securing additional capital to fund our ongoing operations, we believe that the manufacture of clinical material for AB101 in accordance with our pre-determined specifications is the most important near term milestone that must be achieved to successfully start our clinical study in 2016. If we experience any material delays in enabling our sterile manufacturing, the timing for the commencement of our first study will be adversely impacted.

As part of our preparation for our clinical study for AB101, in calendar year 2015 we initiated a dialogue with the FDA through a pre-IND meeting request submission to obtain the agency’s perspective with respect to our preclinical efforts and planned initial clinical studies for AB101. We have received detailed and constructive feedback from the FDA regarding our study plans for AB101 and while we have yet submitted our IND to the FDA, we believe that based upon the written and in-person feedback that we have received from the agency, there is nothing outstanding that would preclude us from studying AB101 in patients. We plan on submitting the IND in the second half of calendar year 2016 and commencing our clinical study shortly thereafter.

Significant Accounting Policies and Estimates

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to share-based payments and warrants, fair value of derivative instruments, useful life of depreciable assets, income tax valuation allowances and contingencies. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under the circumstance, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods, estimates, and judgments used by us in applying these most critical accounting policies have a significant impact on the results we report in our consolidated financial statements.

Results of Operations

For Three and Nine Months Ended March 31, 2016 and 2015

Results of operations for the three months ended March 31, 2016 (the “2016 quarter”) and the three months ended March 31, 2015 (the “2015 quarter”) reflected losses of approximately $3,711,000 and $3,173,000, respectively.

Results of operations for the nine months ended March 31, 2016 (the “2016 period”) and the nine months ended March 31, 2015 (the “2015 period”) reflected losses of approximately $11,065,000 and $8,323,000, respectively.

Revenues

We are a preclinical stage company and have not generated any revenues since inception.

Expenses

Research and development costs include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. Research and development costs were approximately $2,310,000 in the 2016 quarter compared to $1,291,000 in the 2015 quarter. Research and development costs were approximately $6,802,000 in the 2016 period compared to $2,970,000 in the 2015 period. The increase is due to the Company having significant research and development activities during the 2016 period compared to the 2015 period. The Company has hired significant staff as well as begun preparing to manufacture clinical material in the 2016 period as compared to the 2015 period in which the Company was still getting the facilities established as the construction of the lab facilities and the manufacturing suite was not yet completed.

General and administrative costs were approximately $1,405,000 in the 2016 quarter compared to $1,009,000 in the 2015 quarter. General and administrative costs were approximately $4,279,000 in the 2016 period compared to $4,635,000 in the 2015 period. The increase for the 2016 quarter is due to an increase in compensation and benefits as we hired staff during the current year and an increase in general expenses in the 2016 quarter compared to the 2015 quarter as overall operations have increased. The decrease for the 2016 period is due to a decrease in consulting fees and investor relations fees for the 2016 period as we have hired staff and brought significant portions of those roles in house.

Liquidity and Capital Resources

As of March 31, 2016, we have approximately $1.7 million in cash on hand and a working capital deficit of approximately $379,000. During the year ended June 30, 2015, we closed on an equity transaction in which we issued 6,040,921 units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. The Company received net proceeds of approximately $10.1 million from the equity transaction. During the nine months ended March 31, 2016, we closed on Preferred Stock transactions in which we issued 2,742,186 shares of Series A Convertible Preferred Stock. The Company received net proceeds of approximately $4.8 million from the transaction. On April 12, 2016, we closed a final Preferred Stock transaction in which we issued 512,280 shares of series A convertible Preferred Stock and received proceeds of $1 million.

While we do have cash on hand, we anticipate that we will need an additional $15-$18 million to cover operating expenses, the first clinical trial for AB101 and continuing research and development of our product pipeline through the calendar year end 2016 and the first half of calendar year 2017. We are currently in the process of raising additional capital to fund our current and future operations. If for any reason we are unable to secure additional capital, our ongoing prospects will be severely limited and we will be unable to fund our first clinical study for AB101 which we believe is a critical step in demonstrating human proof of concept and materially increasing shareholder value.

Going Concern

The continuation of our business is dependent upon obtaining further financing and achieving a break even or profitable level of operations in our business. The issuance of additional securities by us could result in a significant dilution in the equity interests of our current or future stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. There are no assurances that we will be able to obtain additional financing through either private placements, and/or bank financing or other loans necessary to support our working capital requirements. To the extent that funds generated from operations and any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to us. These conditions raise substantial doubt about our ability to continue as a going concern.

Recent Accounting Pronouncements

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"), which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform assessments of an entity's ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform the going concern assessment under ASU 2014-15 beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition, results of operations or disclosures.

In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20), which eliminates the concept of extraordinary items. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. The new guidance is to be applied prospectively but may also be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We expect to adopt the provisions of this new guidance beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.

Off-Balance Sheet Arrangements

We had no off-balance sheet transactions.

ITEM 3. QUALITATIVE AND QUANTITATIVE DISCUSSION ABOUT MARKET RISK.

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and our Chief Accounting Officer (our principal accounting officer), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based on that evaluation and the material weakness described below, our management concluded that we did not maintain effective disclosure controls and procedures as of March 31, 2016 in ensuring that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that it is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management has identified control deficiencies regarding a lack of segregation of duties, and a need for a stronger internal control environment. Our management believes that these deficiencies, which in the aggregate constitute a material weakness, are due to the small size of our staff, which makes it challenging to maintain adequate disclosure controls.

Changes in internal controls over financial reporting

During the period covered by this Quarterly Report on Form 10-Q, there were no changes in our internal control over financial reporting (as defined in Rule 13(a)-15(f) or 15(d)-15(f)) that occurred during the period covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Certain factors exist which may affect the Company’s business and could cause actual results to differ materially from those expressed in any forward-looking statements. The Company has not experienced any material changes from those risk factors as previously disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 28, 2015 (the “Form 10-K”).

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On February 19, 2016, we agreed to issue warrants to purchase up to 60,000 shares of common stock as compensation for consulting services performed in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act. The warrants contain a cashless exercise rights, and shall be adjusted both as to the number of Financing Warrant Shares and price into which and at which they are exercisable, based on any splits, conversions, or reorganizations that affect the Company’s common stock.

On April 12, 2016, we closed a final offering of our Series A Preferred Stock with one accredited investor. In connection with the close, we entered into a Purchase Agreement by and between us and the investor in which we issued 512,280 Series A Preferred Shares at a purchase price of $1.95 per share. We received gross proceeds of $1 million which was raised by the Company acting as its own agent and therefore the proceeds are not subject to placement agent fees.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit Number		Description of Exhibits

31.1		Certification of Chief Executive Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Certification of Chief Accounting Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Certification of Chief Executive Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2		Certification of Chief Accounting Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101		The following materials from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 formatted in XBRL (eXtensible Business Reporting Language): (i) Balance Sheet, (ii) Statement of Operations, (iii) Statements of Cash Flows, (iv) Statements of Stockholders Equity and (v) related notes to these financial statements, tagged as blocks of text.*

*Filed herewith

SIGNATURES

In accordance with Section 12 of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		ANTRIABIO, INC.

Date: May 16, 2016	By:	/s/ Nevan Elam
		Nevan Elam
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 16, 2016	By:	/s/ Morgan Fields
		Morgan Fields
		Chief Accounting Officer
		(Principal Accounting Officer)

EX-31.1 2 v438591_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Nevan Elam, certify that:

I have reviewed this quarterly report on Form 10-Q of AntriaBio, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

As the Registrant's sole certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

As the Registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date:

May 16, 2016

	By:	/s/ Nevan Elam
		Nevan Elam
		Principal Executive Officer

EX-31.2 3 v438591_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATIONS

I, Morgan Fields, certify that:

I have reviewed this quarterly report on Form 10-Q of AntriaBio, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date:

May 16, 2016

	By:	/s/ Morgan Fields
		Morgan Fields
		Principal Accounting Officer

EX-32.1 4 v438591_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AntriaBio, Inc. Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nevan Elam, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:

May 16, 2016

	By:	/s/ Nevan Elam
		Nevan Elam
		Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to AntriaBio, Inc. Inc. and will be retained by AntriaBio, Inc. Inc. to be furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v438591_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AntriaBio, Inc. Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Morgan Fields, Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:

May 16, 2016

	By:	/s/ Morgan Fields
		Morgan Fields
		Principal Accounting Officer

EX-101.INS 6 antb-20160331.xml XBRL INSTANCE DOCUMENT 0001509261 2015-01-01 2015-03-31 0001509261 2016-01-01 2016-03-31 0001509261 2016-03-31 0001509261 2014-05-01 2014-05-31 0001509261 2016-05-16 0001509261 2014-05-31 0001509261 2015-06-30 0001509261 2014-07-01 2015-03-31 0001509261 2014-07-01 2015-06-30 0001509261 2015-07-01 2016-03-31 0001509261 2014-06-30 0001509261 2015-03-31 0001509261 us-gaap:CommonStockMember 2014-07-01 2015-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2014-07-01 2015-06-30 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2014-07-01 2015-06-30 0001509261 us-gaap:CommonStockMember 2015-07-01 2016-03-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2015-07-01 2016-03-31 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2015-07-01 2016-03-31 0001509261 us-gaap:CommonStockMember 2014-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2014-06-30 0001509261 us-gaap:CommonStockMember 2015-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2015-06-30 0001509261 us-gaap:CommonStockMember 2016-03-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001509261 antb:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2016-03-31 0001509261 antb:LeasePayableMember 2015-07-01 2016-03-31 0001509261 antb:LeasePayableMember 2014-07-01 2015-03-31 0001509261 antb:TenantImprovementsMember 2014-07-01 2015-03-31 0001509261 antb:TenantImprovementsMember 2015-07-01 2016-03-31 0001509261 antb:AccountsPayableAndAccruedExpensesMember 2015-07-01 2016-03-31 0001509261 antb:AccountsPayableAndAccruedExpensesMember 2014-07-01 2015-03-31 0001509261 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001509261 us-gaap:EquipmentMember 2016-03-31 0001509261 antb:Equipment1Member 2016-03-31 0001509261 us-gaap:LeaseholdImprovementsMember 2016-03-31 0001509261 us-gaap:ConstructionInProgressMember 2016-03-31 0001509261 us-gaap:FurnitureAndFixturesMember 2015-06-30 0001509261 us-gaap:EquipmentMember 2015-06-30 0001509261 antb:Equipment1Member 2015-06-30 0001509261 us-gaap:LeaseholdImprovementsMember 2015-06-30 0001509261 us-gaap:ConstructionInProgressMember 2015-06-30 0001509261 us-gaap:ConstructionInProgressMember 2015-07-01 2016-03-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2014-06-30 0001509261 us-gaap:ConvertibleNotesPayableMember 2013-07-01 2014-06-30 0001509261 antb:TwoThousandAndThirteenNotesMember 2013-12-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2016-03-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2015-06-30 0001509261 antb:TwoThousandAndThirteenNotesMember 2014-03-01 2014-03-31 0001509261 us-gaap:ConvertibleNotesPayableMember 2014-03-01 2014-03-31 0001509261 antb:TwoThousandAndThirteenNotesMember 2014-03-31 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-10 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-01 2015-12-10 0001509261 antb:SeriesConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2015-12-01 2015-12-10 0001509261 antb:SeriesConvertiblePreferredStockMember us-gaap:WarrantMember 2015-12-01 2015-12-10 0001509261 antb:InvestorRelationsMember 2014-07-01 2015-06-30 0001509261 us-gaap:PrivatePlacementMember 2014-07-01 2015-06-30 0001509261 us-gaap:WarrantMember 2014-07-01 2015-06-30 0001509261 us-gaap:PrivatePlacementMember 2015-06-30 0001509261 us-gaap:EmployeeStockOptionMember antb:EmployeesAndDirectorsMember 2013-01-01 2013-01-31 0001509261 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember antb:EmployeesAndDirectorsMember 2013-01-01 2013-01-31 0001509261 antb:EmployeesAndDirectorsMember 2013-05-01 2013-05-31 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember 2015-07-01 2016-03-31 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember us-gaap:MinimumMember 2014-03-01 2014-03-26 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember us-gaap:MaximumMember 2014-03-01 2014-03-26 0001509261 antb:TwoThousandAndFourteenStockAndIncentivePlanMember 2014-03-26 0001509261 antb:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2015-07-01 2016-03-31 0001509261 antb:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2015-02-01 2015-02-23 0001509261 antb:EmployeesAndDirectorsMember us-gaap:EmployeeStockOptionMember 2015-02-23 0001509261 antb:TwoConsultantsMember 2014-07-01 2015-06-30 0001509261 antb:EmployeesAndDirectorsMember antb:TwoThousandAndFourteenStockAndIncentivePlanMember us-gaap:MinimumMember 2015-02-01 2015-02-23 0001509261 antb:TwoThousandAndFourteenStockAndIncentivePlanMember antb:EmployeesAndDirectorsMember 2015-02-01 2015-02-23 0001509261 us-gaap:EmployeeStockOptionMember 2014-07-01 2015-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2015-07-01 2016-03-31 0001509261 us-gaap:EmployeeStockOptionMember 2015-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2016-03-31 0001509261 us-gaap:EmployeeStockOptionMember 2014-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2013-07-01 2014-06-30 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember antb:EmployeesAndDirectorsMember 2016-01-01 2016-03-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember antb:EmployeesAndDirectorsMember 2016-01-01 2016-03-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember antb:EmployeesAndDirectorsMember 2015-07-01 2016-03-31 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember antb:EmployeesAndDirectorsMember 2015-07-01 2016-03-31 0001509261 us-gaap:WarrantMember 2014-06-30 0001509261 us-gaap:WarrantMember 2015-07-01 2016-03-31 0001509261 us-gaap:WarrantMember 2015-06-30 0001509261 us-gaap:WarrantMember 2016-03-31 0001509261 us-gaap:WarrantMember 2013-07-01 2014-06-30 0001509261 antb:WarrantOneMember 2015-06-30 0001509261 antb:WarrantTwoMember 2015-06-30 0001509261 antb:WarrantThreeMember 2015-06-30 0001509261 antb:WarrantFourMember 2015-06-30 0001509261 antb:WarrantFifteenMember 2016-03-31 0001509261 antb:WarrantFifteenMember 2015-07-01 2016-03-31 0001509261 antb:WarrantSixteenMember 2016-03-31 0001509261 antb:WarrantSeventeenMember 2016-03-31 0001509261 antb:AdditionalPaidinCapitalAndProfessionalFeeMember 2016-03-31 0001509261 antb:WarrantSixteenMember 2015-07-01 2016-03-31 0001509261 antb:WarrantSeventeenMember 2015-07-01 2016-03-31 0001509261 us-gaap:WarrantMember antb:AdditionalPaidinCapitalAndProfessionalFeeMember 2016-03-31 0001509261 antb:WarrantEighteenMember antb:LatticeModelMember 2016-03-31 0001509261 antb:WarrantEighteenMember antb:DerivativeExpenseMember 2015-02-23 0001509261 antb:BlackScholesPricingModelMember 2015-02-01 2015-02-23 0001509261 antb:BlackScholesPricingModelMember 2015-02-23 0001509261 antb:WarrantNinteenMember 2016-03-31 0001509261 antb:LatticeModelMember 2016-03-31 0001509261 antb:WarrantNinteenMember 2015-04-06 0001509261 antb:LatticeModelMember 2015-04-06 0001509261 antb:DerivativeExpenseMember antb:WarrantEighteenMember 2015-04-06 0001509261 antb:WarrantOneMember 2016-03-31 0001509261 antb:WarrantTwoMember 2016-03-31 0001509261 antb:WarrantThreeMember 2016-03-31 0001509261 us-gaap:InvestorMember 2016-03-31 0001509261 antb:WarrantTwelveMember 2015-07-01 2016-03-31 0001509261 antb:WarrantThirteenMember 2015-07-01 2016-03-31 0001509261 us-gaap:WarrantMember antb:LatticeModelMember 2016-03-31 0001509261 antb:WarrantTwelveMember 2016-03-31 0001509261 antb:LatticeModelOneMember 2016-03-31 0001509261 antb:LatticeModelTwoMember 2015-03-31 0001509261 us-gaap:CapitalLeaseObligationsMember 2014-09-30 0001509261 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2015-07-01 2016-03-31 0001509261 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2015-07-01 2016-03-31 0001509261 us-gaap:EquipmentMember us-gaap:MinimumMember 2015-07-01 2016-03-31 0001509261 us-gaap:EquipmentMember us-gaap:MaximumMember 2015-07-01 2016-03-31 0001509261 antb:Equipment1Member us-gaap:MinimumMember 2015-07-01 2016-03-31 0001509261 antb:Equipment1Member us-gaap:MaximumMember 2015-07-01 2016-03-31 0001509261 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2015-07-01 2016-03-31 0001509261 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2015-07-01 2016-03-31 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-03-02 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-03-01 2016-03-31 0001509261 us-gaap:PrivatePlacementMember antb:SeriesConvertiblePreferredStockMember 2016-03-01 2016-03-31 0001509261 us-gaap:WarrantMember antb:SeriesConvertiblePreferredStockMember 2016-03-01 2016-03-31 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-01-01 2016-03-31 0001509261 antb:SeriesConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2016-04-12 0001509261 antb:SeriesConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2016-04-01 2016-04-12 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-07 0001509261 antb:SeriesConvertiblePreferredStockMember 2015-12-01 2015-12-07 0001509261 antb:SeriesConvertiblePreferredStockMember 2016-03-31 0001509261 antb:BlackScholesPricingModelMember us-gaap:MinimumMember 2015-07-01 2016-03-31 0001509261 antb:BlackScholesPricingModelMember us-gaap:MaximumMember 2015-07-01 2016-03-31 0001509261 antb:BlackScholesPricingModelMember 2015-07-01 2016-03-31 0001509261 antb:LatticeModelOneMember us-gaap:MinimumMember 2015-07-01 2016-03-31 0001509261 antb:LatticeModelOneMember us-gaap:MaximumMember 2015-07-01 2016-03-31 0001509261 antb:LatticeModelOneMember us-gaap:WarrantMember 2015-07-01 2016-03-31 0001509261 antb:LatticeModelTwoMember us-gaap:WarrantMember 2015-07-01 2016-03-31 0001509261 antb:WarrantFourMember 2016-03-31 0001509261 antb:WarrantFourMember 2015-07-01 2016-03-31 0001509261 us-gaap:ConvertiblePreferredStockMember 2016-03-31 0001509261 us-gaap:ConvertiblePreferredStockMember 2015-06-30 0001509261 antb:LatticeModelOneMember 2015-07-01 2016-03-31 0001509261 antb:LatticeModelTwoMember 2015-07-01 2016-03-31 0001509261 antb:WarrantFourteenMember 2016-01-01 2016-03-31 0001509261 antb:CompensationForServicesMember 2014-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:sqft xbrli:pure 10-Q false 2016-03-31 2016 Q3 AntriaBio, Inc. 0001509261 --06-30 Smaller Reporting Company ANTB 24338219

53437

58906

562500

93852

14579

13079

11679

31777

2419129

1705778

431341

480490

23127

431341

503617

60000

1408399

2168973

11263202

8790850

5146818

6750550

563000

4524912

6134613

6116384

2040300

387511

294278

60000

116952

98671

46946

24341

41268207

38138754

-40173970

-29109288

1118578

9053807

8790850

11263202

5278706

1746022

2850470

2209395

450167

4821802

302731

628252 1180350 166472 265470

296385

461599

36602 88138

4640

33000 0 780500 907626

72270

106791

2300200

3715475

-2300200

-3715475

87033

1093

2086

1143

-871447

5782

-872440

-3172640

-3710835

-0.14

-0.15

22542821

24338219

402770 199686

706380

1306806 3187751 425891 869750

871308

1837110

468047 202458

16928

349633 0 2828032 3025476

362339

344964

7604344

11081610

-7604344

-11081610

626777

4062

965

4885

4135

-717733

20098

-718556

-8322900

-11064682

-0.42

-0.46

19840425

24338219

907721 365511

2846828

368419

207

368212

205506

-11064682

2877628

6026070

4768123

6042

4762081

6040921

-11362364

6406731

18092

24135563

-17746924

18091792

313104

24341

38138754

-29109288

24341

41268207

-40173970

24338219

3432

5469

91021

476941

1864226

2877628

298418

-5115746

-7336591

2290184

-3532684

-529394

1500

57017 -30868

8785945

4940653

-1380015

45019 70033 84558 62941

-105577

93767

450055

-450167

5934534

8224718

874960

1774413

-1136746

-187500

184877

511616

380727

448345

55000

9761070

336929

930106

250163 1671618

5347615

312229

484716

11679

20098 378829

62730

3378355

113965

3191792

55330

889671

1371441

29296

2315803

612229

136629

P0Y

256404

33113

99000 33000

1.50

3032500

653000

0.08

3000000

1.26 1.26

1.89

2703000

60000

0.08

60000

2186838

4275172

3111126

2703000

1.95

1025699

1803548

105715

90852

166668

296669

6040921

10100000

37838

70000

2072911

1071568

P36M

2.50

1500000

4.50

819445 541667

138888

4162000

1.29

3.44

3750000

3295000

2.06

6850000

8334

4.50

1.40

P3Y P4Y

4572000

50000

212916

P5Y

8702418

35000

8717418

P6Y4M24D

3.61

2.02

1.40

3.57

1.75

2.78

2.77

P7Y1M6D

P5Y7M6D

4041063

3.27

4343334

613710

297925

8599608

917892

1959736

11099739

6040921 1824489 111000 87000 59758

19016391

19345381

2.21 1.70 2.92 2.32 2.50 2.50 1.63 2.33

P3Y7M6D

P3Y

P2Y3M18D

271990 30000 3.44 2.39

6040921

1824489

105000

6000

2.50

1.65

1.38

66667

31777 11679

50365

105000

4968482

1072439

80677 3527816 1009433

2597932

595184

6000 9006

1418373

99650

2217605

92111

58914

1477287 347202 172809

1498809

247552 309121 124434

9000

1.38

18000

1.34

60000

1.85

9000

17412 34122

1518387

11407

18000 271990

1418373

1498809

99650

172809

28939

0.03 34381

27000

750000

187500

392855

335747

91208

370252

381360

8075

24223

48446

1500

46946

0.001

5000000

0.001

200000000

24338219

2310189

1290795

6802332

2969516

1405286

1009405

4279278

4634828

0 132339 0 2217605

61279

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <b><u></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><u><b><u>Note 3 Going Concern</u></b></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As reflected in the accompanying financial statements, the Company has a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,064,682</font> and net cash used in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,336,591</font> for the nine months ended March 31, 2016, and working capital deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">378,829</font> and stockholders’ equity of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,118,578</font> with an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,173,970</font> at March 31, 2016. In addition, the Company is in the preclinical stage and has not yet generated any revenues. These factors raise substantial doubt about the Company’s ability to continue as a going concern.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on Management's plans, which include continuing to raise capital through issuances of common and preferred stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the satisfaction of the liabilities that might be necessary should the Company be unable to continue as a going</font> concern.</div> </div> </div> </div> </div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><u><font style="FONT-SIZE: 10pt"> </font></u></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <strong><u></u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <strong><u></u></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><u><strong><u><font style="FONT-SIZE: 10pt">Note 9 Stock-Based Compensation</font></u></strong></u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><i> Options</i> - AntriaBio adopted individual stock option plans in January 2013 for four officers and/or directors of the Company. The stock option plans granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> option shares with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share. Options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 819,445</font> shares vested immediately, options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 541,667</font> shares vest monthly over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font> years and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 138,888</font> shares vest on May 31, 2013. In June 2013, AntriaBio adopted individual stock option plans for two consultants of the Company. The stock option plans granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,334</font> shares with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share and had fully vested as of June 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 26, 2014, the Company adopted the AntriaBio, Inc. 2014 Stock and Incentive Plan which allows the Company to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,750,000</font> of common stock in the form of stock options, incentive options or common stock. As of March 31, 2016, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,295,000</font> of these shares to current employees and directors of the Company. The options have an exercise price from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.29</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.44</font> per share. The options vest monthly over four years, with some options subject to a one year cliff before options begin to vest monthly.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 23, 2015, the Company adopted the AntriaBio, Inc. 2015 Non Qualified Stock Option Plan which allows the Company to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,850,000</font> of common stock in the form of stock options. As of March 31, 2016, the Company had granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,162,000</font> of these shares to current employees and directors of the Company. The options have an exercise price of from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.40</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.06</font> per share. The options vest monthly over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font> years with some options subject to a one year cliff before options begin to vest monthly.</font></div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">AntriaBio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of peer companies. Due to the small number of option holders and all options being to officers and/or directors, AntriaBio has estimated a forfeiture rate of zero as the value of each option holder is calculated individually. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2016 using the following assumptions:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock option activity is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Expected Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,343,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,572,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(212,916)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,702,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(35,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,717,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Exercisable at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,041,063</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development  compensation and benefits expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">297,925</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">917,892</font>, respectively, and as general and administrative  compensation and benefits expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">613,710</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,959,736</font>, respectively, for the three and nine months ended March 31, 2016. The unrecognized stock-based compensation expense at March 31, 2016 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,599,608</font>. AntriaBio determined the fair value as of the date of grant using the Black-Scholes option pricing method and expenses the fair value ratably over the vesting period.</font></div> <i><font style="FONT-SIZE: 10pt"> </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Warrants<strong>-</strong></font></i> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,099,739</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued in private placement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,040,921</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,824,489</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued for investor relations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>111,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(59,758)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,016,391</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued for investor relations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>271,990</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(30,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,345,381</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Year Ended June 30, 2015:</font></u> <font style="FONT-SIZE: 10pt">The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,040,921</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.50</font> per share, exercisable through April 2018 in connection with the issuance of units in private placements. The Company issued warrants to the placement agent to purchase agent to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,824,489</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.50</font> per share, exercisable through April 2022 in connection with the private placements that occurred from November 2014 through April 2015. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 105,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.65</font> per share in connection with investor relations services. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.38</font> per share in connection with investor relations services.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">For the Nine Months Ended March 31, 2016:</font></u> <font style="FONT-SIZE: 10pt">The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.38</font> per share in connection with investor relations services. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.34</font> per share in connection with investor relations services. The Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.85</font> per share in connection with investor relations services. The Company issued warrants to the placement agents to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 271,990</font> shares of common stock at a weighted average price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.39</font> per share, exercisable through October 2023 in connection with the preferred stock offering that occurred during the nine months ended March 31, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66,667</font> shares of common stock are accounted for under liability accounting for the shares that have vested and were recorded at their fair value on the date of issuance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,365</font> as a liability and as professional fees and investor relation expense. Warrants for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000</font> shares of the common stock were cancelled as of December 31, 2015 as the vesting events for the warrants had not occurred. The fair value as of March 31, 2016 and June 30, 2015 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,679</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,777</font>, respectively which is reflected as a liability with the fair value adjustment recorded as derivative gains or losses on the consolidated statements of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,968,482</font> shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,527,816</font> and the allocated fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,597,932</font> was recorded into additional paid-in capital. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,072,439</font> shares of common stock were accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The estimated fair value of the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,009,433</font> and the allocated fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">595,184</font> was recorded into additional paid-in capital. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 105,000</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,677</font> and recorded as additional paid-in-capital and professional fees. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,006</font> and recorded as additional paid-in-capital and professional fees.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,000</font> shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,407</font> and recorded as additional paid-in-capital and investor relations. The additional warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,000</font> shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,412</font> and recorded as additional paid-in-capital and investor relations. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> shares of common stock were accounted for under the equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,122</font> and recorded as additional paid-in-capital and investor relations. The warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 271,990</font> shares of common stock were accounted for under equity treatment and were fair valued as of the date of issuance. The fair value of the warrants was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,163</font></font> and recorded as additional paid-in-capital and Series A Convertible Preferred Stock as issuance costs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,477,287</font> shares were accounted for under liability accounting on the date they were recorded, except for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 58,914</font> shares which were recorded directly into equity using the Black-Scholes pricing model on February 23, 2015 at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">92,111</font>. The warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,418,373</font> shares had a value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,498,809</font> when originally recorded using a Lattice pricing model and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,217,605</font> as of February 23, 2015 using a Black-Scholes pricing model when the warrant terms became fixed and were reclassified into equity with the fair value adjustment recorded as derivative expense on the consolidated statement of operations. The warrants exercisable for the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 347,202</font> shares were accounted for under liability accounting on the date they were recorded, except for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 247,552</font> shares which were recorded directly into equity using the Black-Scholes pricing model on April 6, 2015 at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">309,121</font>. The warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99,650</font> shares had a value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">172,809</font> when originally recorded using a Lattice pricing model and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">124,434</font> as of April 6, 2015 using a Black-Scholes pricing model when the warrant terms became fixed and were reclassified into equity with the fair value adjustment recorded as derivative expense on the consolidated statement of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The warrants were valued using the Black-Scholes option pricing model on the date of issuance except for the warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,518,387</font> shares which were valued using a Lattice pricing model. In order to calculate the fair value of the warrants in both models, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and warrant term. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of a peer company. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</font></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Significant assumptions were as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>82% - 124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.56% - 2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1 - 7.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We utilize a Lattice model to determine the fair market value of the warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,418,373</font> shares on the day they were issued. The warrants issued resulted in a warrant derivative liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,498,809</font> on the dates they were issued. The Lattice model accommodates the probability of exercise price adjustment features as outlined in the placement agent agreement. Under the terms of the placement agent agreement, until the final close of the private placement financing under the agreement, the exercise price per share can be reduced in proportion to the exercise price per share of warrants issued in the private placement that is lower than the exercise price per share as stated in the warrant agreement. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The estimated fair value was derived using the lattice model with the following assumptions:</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>90% - 91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89% - 1.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We utilize a Lattice model to determine the fair market value of the warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99,650</font> shares on March 31, 2015, the day they were issued. The warrants issued resulted in a warrant derivative liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">172,809</font> on the date they were issued. The Lattice model accommodates the probability of exercise price adjustment features as outlined in the placement agent agreement. Under the terms of the placement agent agreement, until the final close of the private placement financing under the agreement, the exercise price per share can be reduced in proportion to the exercise price per share of warrants issued in the private placement that is lower than the exercise price per share as stated in the warrant agreement.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The estimated fair value was derived using the lattice model with the following assumptions:</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Fair Value of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 1: Quoted prices for identical assets and liabilities in active markets;</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The carrying amounts of financial instruments including cash, restricted cash, accounts payable and accrued expenses, and convertible notes payable approximated fair value as of March 31, 2016 and June 30, 2015 due to the relatively short maturity of the respective instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The warrant derivative liability recorded as of March 31, 2016 and June 30, 2015 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value measurement with the entire change in the balance recorded through earnings. See significant assumptions in Note 9. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(31,777)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Total unrealized gains (losses):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Included in earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">20,098</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Balance as of March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(11,679)<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(31,777)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Total unrealized gains (losses):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Included in earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">20,098</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Balance as of March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(11,679)<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following is a summary of fixed assets and accumulated depreciation:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>Useful</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>June 30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5 - 7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>62,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>55,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3 - 15 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,378,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>889,671</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Lab equipment (not yet placed in service)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3 - 15 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>113,965</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,371,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3 - 7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,191,792</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,296</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Construction in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,315,803</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,746,842</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,661,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(612,229)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(136,629)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,134,613</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,524,912<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Stock option activity is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Expected Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,343,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,572,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(212,916)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,702,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(35,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,717,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Exercisable at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,041,063</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

61279

31777

61279

6746842

4661541

P5Y

P7Y

P3Y

P15Y

P3Y

P15Y

P3Y

P7Y

1.95

1716487

2956975

231214

159311

8169

27236

1.95

512820

1000000

3144479

15000000

1.95

0.06

1.95

The Series A Stock has a conversion feature at the option of the holder that can be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also have a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Company’s listing to NASDAQ Stockmarket or the NYSE MKT and the Company’s common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stock’s conversion price is subject to weighted average anti-dilution protection, as defined, and is subject to adjustments for stock splits, dividends, and similar events.

1571422

0.0191

P7Y

0.82

1.24

0.0056

0.0221

P1Y

P7Y6M

0.9

0.91

0.0189

0.0198

P7Y

0.9

0.0171

P7Y

271990

2.39

0.01

1.95

15000000

2769422

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Significant assumptions were as follows: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>82% - 124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.56% - 2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1 - 7.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The estimated fair value was derived using the lattice model with the following assumptions:<font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>90% - 91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89% - 1.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The estimated fair value was derived using the lattice model with the following assumptions:<font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrant term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 250163 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><strong> </strong></font></i><font style="FONT-SIZE: 10pt">AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>11,099,739</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued in private placement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,040,921</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,824,489</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued for investor relations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>111,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(59,758)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,016,391</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued for investor relations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>87,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>271,990</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(30,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding, March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 3px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,345,381</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 500000

61279

-3772114

-3172640

-11125961

-8322900

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><u>Note 2 Summary of Significant Accounting Policies</u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed on September 28, 2015, which contains the audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the year ended June 30, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2016 are not necessarily indicative of results for the full fiscal year.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Risks and Uncertainties</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Restricted Cash</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Restricted cash consisted of cash held in a joint account with our general contractor until the completion of the construction in progress. As the construction process was completed as of December 31, 2015, the restricted cash was released and used to pay the final invoices to the general contractor.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development Costs</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other costs. These costs relate to research and development costs without an allocation of general and administrative expenses.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 1: Quoted prices for identical assets and liabilities in active markets;</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The carrying amounts of financial instruments including cash, restricted cash, accounts payable and accrued expenses, and convertible notes payable approximated fair value as of March 31, 2016 and June 30, 2015 due to the relatively short maturity of the respective instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The warrant derivative liability recorded as of March 31, 2016 and June 30, 2015 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value measurement with the entire change in the balance recorded through earnings. See significant assumptions in Note 9. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(31,777)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Total unrealized gains (losses):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Included in earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">20,098</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Balance as of March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(11,679)<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, <i>Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern</i> ("ASU 2014-15"), which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform assessments of an entity's ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform the going concern assessment under ASU 2014-15 beginning with the year ending June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition, results of operations or disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In January 2015, the FASB issued ASU 2015-01, <i> Income Statement  Extraordinary and Unusual Items (Subtopic 225-20)</i>, which eliminates the concept of extraordinary items. The new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. The new guidance is to be applied prospectively but may also be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We expect to adopt the provisions of this new guidance beginning with the year ended June 30, 2017. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2015, the FASB issued ASU 2015-17, <i> Income Taxes: Balance Sheet Classification of Deferred Taxes,</i> which is intended to improve how deferred taxes are classified on organizations’ balance sheets by eliminating the current requirement for organizations to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, organizations will now be required to classify all deferred tax assets and liabilities as noncurrent. The changes are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We expect to adopt the provisions of this new guidance on July 1, 2016. We do not expect the adoption of the new provisions to have a material impact on our financial condition or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In January 2016, the FASB issued ASU 2016-01, <i> Financial Instruments  Overall</i>: <i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 will be effective for us starting on July 1, 2018, and early adoption is not permitted. We are currently evaluating the impact that the standard will have on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In February 2016, the FASB issued ASU 2016-02, <i> Leases (Topic 842)</i>. This update requires organizations to recognize lease assets and lease liabilities on the balance sheet and also disclose key information about leasing arrangements. This ASU is effective for annual reporting periods beginning on or after December 15, 2018, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual period. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09. <i>Compensation  Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.</i> The update will affect all entities that issue share-based payment awards to their employees and is effective for annual periods beginning after December 15, 2016 for public entities. The areas for simplification in ASU 2016-09 involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We are currently evaluating the impact the adoption of this ASU will have on our consolidated financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 7 antb-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Nature of Operations link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Fixed Assets link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Series A Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fixed Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Going Concern (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Fixed Assets (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Fixed Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Convertible Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Series A Convertible Preferred Stock (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Shareholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Stock-Based Compensation (Details 3) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Stock-Based Compensation (Details 4) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Stock-Based Compensation (Details 5) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Commitments and Contingencies (Details 1) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 antb-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 antb-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 antb-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Going Concern [Abstract] Going Concern Disclosure [Text Block] Going Concern Disclosure [Text Block] Disclosure for going concern text block during the reporting period. Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders Equity Note Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share Based Compensation [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Accounting Policies [Abstract] Basis Of Accounting, Policy [Policy Text Block] Use Of Estimates, Policy [Policy Text Block] Risks and Uncertainties [Policy Text Block] Disclosure of accounting policy for the risks and uncertainties during the reporting period. Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Statement Of Financial Position [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Assets [Abstract] Assets Assets Current [Abstract] Current assets Cash Cash Cash - Beginning of Period Cash - End of Period Restricted Cash and Cash Equivalents Restricted cash Other Assets, Current Other current assets Assets, Noncurrent [Abstract] Non-current assets Property, Plant and Equipment, Net, Total Fixed assets, net Property, Plant and Equipment, Net Intangible Assets, Net (Excluding Goodwill), Total Intangibile assets, net Deposits Assets, Noncurrent Deposit Assets, Noncurrent, Total Total non-current assets Assets, Total Total Assets Liabilities Current [Abstract] Current liabilities: Liabilities, Noncurrent [Abstract] Non-current liabilities: Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Convertible Notes Payable, Current Convertible notes payable Other Liabilities, Current Deferred lease liability, current portion Capital Lease Obligations, Current Lease payable, current portion Lease payable, current portion Interest Payable, Current Interest payable Derivative Liabilities, Current Warrant derivative liability Liabilities, Current, Total Total current liabilities Liabilities, Total Total Liabilities Other Liabilities, Noncurrent Deferred lease liability, less current portion Capital Lease Obligations, Noncurrent Lease payable, less current portion Liabilities, Noncurrent, Total Total non-current liabilities Commitments and Contingencies Commitments and Contingencies (Note 11) Temporary Equity, Carrying Amount, Attributable to Parent Series A Convertible Preferred Stock - subject to redemption, $0.01 par value, $1.95 redemption value; 15,000,000 authorized; 2,769,422 and no shares issued and outstanding, March 31, 2016 and June 30, 2015, respectively Stockholders Equity [Abstract] Stockholders' equity: Preferred Stock Value Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued and outstanding Common Stock Value Common stock, $0.001 par value, 200,000,000 shares authorized; 24,338,219 and 24,338,219 shares issued and outstanding, March 31, 2016 and June 30, 2015 Additional Paid In Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable To Parent Total stockholders' equity Total Stockholders' Equity Balance Balance Liabilities and Stockholders Equity Total Liabilities, Series A Convertible Preferred Stock and Stockholders' Equity Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Share-Based Compensation [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Valuation Technique [Axis] Valuation Technique [Domain] Black Scholes Pricing Model [Member] Black Scholes Pricing Model Lattice Model One [Member] Lattice Model One Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Warrants Issued To Agents Activity [Table Text Block] Schedule Of Warrants Issued To Agents Activity [Table Text Block] Schedule of warrants issued to agents activity [Table Text Block] Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Schedule of share based payment award stock warrants valuation assumptions [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Summary of Significant Accounting Policies [Table] Summary of Significant Accounting Policies Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies Financial Instruments, Owned, at Fair Value, Total Balance as of June 30, 2015 Balance as of March 31, 2016 Financial Instruments Total Unrealized Gains [Abstract] Total unrealized gains (losses): Fair Value Of Financial Instruments Earnings Included in earnings Fair value of financial instruments earnings Going Concern [Table] This table lists the going concern. Going Concern [Line Items] The line items identify information about the going concern. Net Income (Loss) Attributable To Parent Net Loss Net loss Net loss Net Loss Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Used In Operating Activities Net Cash Used In Operating Activities Working Capital Deficit Working Capital Deficit Working capital deficit. Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Title of Individual [Axis] Relationship to Entity [Domain] Eligible Item or Group for Fair Value Option [Axis] Fair Value, Option, Eligible Item or Group [Domain] Balance Sheet Location [Axis] Consulting Expenses Consulting expenses Consulting expenses Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Convertible Notes Payable [Table] This table lists the convertible notes payable. Short-Term Debt, Type [Axis] Short-Term Debt, Type [Domain] Convertible Notes Payable [Member] Convertible Notes Payable Two Thousand And Thirteen Notes [Member] 2013 Notes Range [Axis] Range [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Income Statement Location [Axis] Income Statement Location [Domain] Convertible Notes Payable [Line Items] The line items identify information about the convertible notes payable. Qualified Financing Qualified financing Qualified financing Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate, stated percentage Debt Instrument, Convertible, Conversion Price Debt instrument, convertible, conversion price Debt Conversion, Converted Instrument, Amount Debt conversion, converted instrument, amount Debt Instrument, Convertible, Beneficial Conversion Feature Beneficial conversion feature recorded as a debt discount Marketable Securities, Equity Securities, Current, Total Marketable securities, equity securities, current, total Common Stock Convertible Conversion Price Common stock convertible conversion price Common Stock convertible conversion Price. Investment Option Convertible Conversion Price Investment option convertible conversion price Investment option convertible conversion price. Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Stock by Class [Table] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Private Placement [Member] Private Placement Investor Relations [Member] Investor Relations Plan Name [Axis] Plan Name [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Award Type [Axis] Equity Award [Domain] Warrant [Member] Warrant Issuance Of Common Stock Shares Stock issued during period, shares, new issues Issuance of common stock, net of issuance costs of $3,144,479 (in shares) Proceeds from Issuance of Private Placement Proceeds from issuance of private placement Payments of Stock Issuance Costs Payments of stock issuance costs Class Of Warrant Or Right Of Warrants Or Rights Expiring Period Class of warrant or right of warrants or rights expiring period Class of warrant or right of warrants or rights expiring period. Adjustments to Additional Paid in Capital, Warrant Issued Adjustments to Additional Paid in Capital, Warrant Issued Fair value of warrants issued Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Warrant term (years) Warrant term (years) Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Dividend yield Option Indexed to Issuer's Equity [Axis] Employee Stock Option [Member] Stock Option Employee Stock Option Statement [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Outstanding Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Granted Share-based compensation arrangement by share-based payment award, options, grants in period, gross Stock Issued During Period, Shares, Share-based Compensation, Forfeited Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Outstanding Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Granted Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Expected Life Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number Number of Warrants - Outstanding Number of Warrants - Outstanding Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued To Private Placement Number of Warrants - Warrants issued in private placement Share based compensation arrangement by share based payment award equity instruments other than options warrants issued to private placement. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued To Placement Agent Number of Warrants - Warrants issued to placement agent Share based compensation arrangement by share based payment award equity instruments other than options warrants issued to placement agent Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued For Investyor Relations Number of Warrants - Warrants issued for investor relations Share based compensation arrangement by share based payment award equity instruments other than options warrants issued for investor relations. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants cancelled In Period Number of Warrants - Warrants cancelled The number of warrants that were cancelled during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price Weighted Average Exercise Price - Outstanding Weighted Average Exercise Price - Outstanding Share based compensation arrangement by share based payment award equity instruments other than options non vested weighted average exercise price Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued To Private Placement Weighted Average Exercise Price - Warrants issued in private placement Share based compensation arrangement by share based payment award equity instruments other than options exercise price warrants issued to private placement. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued To Placement Agent Weighted Average Exercise Price - Warrants issued to placement agent Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued To Placement Agent. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued For Investyor Relations Weighted Average Exercise Price - Warrants issued for investor relations Share based compensation arrangement by share based payment award equity instruments other than options exercise price warrants issued for investor relations. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price Warrants Cancelled In Period Weighted Average Exercise Price - Warrants cancelled Share based compensation arrangement by share based payment award equity instruments other than options non vested weighted average exercise price warrants cancelled. Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Remaining Contractual Terms Weighted Average Remaining Contractual Life - Outstanding Major Types Of Debt and Equity Securities [Axis] Major Types Of Debt and Equity Securities [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Share-based Arrangements with Employees and Nonemployees [Abstract] Financial Instrument [Axis] Financial Instruments [Domain] Warrant One [Member] Warrant One Warrant Two [Member] Warrant Two Warrant Three [Member] Warrant Three EX-101.PRE 11 antb-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	May. 16, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Registrant Name	AntriaBio, Inc.
Entity Central Index Key	0001509261
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ANTB
Entity Common Stock, Shares Outstanding		24,338,219

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current assets
Cash	$ 1,746,022	$ 5,278,706
Restricted cash	0	450,167
Other current assets	294,278	387,511
Total current assets	2,040,300	6,116,384
Non-current assets
Fixed assets, net	6,134,613	4,524,912
Intangibile assets, net	53,437	58,906
Deposit	562,500	563,000
Total non-current assets	6,750,550	5,146,818
Total Assets	8,790,850	11,263,202
Current liabilities:
Accounts payable and accrued expenses	2,168,973	1,408,399
Convertible notes payable	60,000	60,000
Deferred lease liability, current portion	116,952	98,671
Lease payable, current portion	46,946	93,852
Interest payable	14,579	13,079
Warrant derivative liability	11,679	31,777
Total current liabilities	2,419,129	1,705,778
Non-current liabilities:
Deferred lease liability, less current portion	431,341	480,490
Lease payable, less current portion	0	23,127
Total non-current liabilities	431,341	503,617
Total Liabilities	$ 2,850,470	$ 2,209,395
Commitments and Contingencies (Note 11)
Series A Convertible Preferred Stock - subject to redemption, $0.01 par value, $1.95 redemption value; 15,000,000 authorized; 2,769,422 and no shares issued and outstanding, March 31, 2016 and June 30, 2015, respectively	$ 4,821,802	$ 0
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 24,338,219 and 24,338,219 shares issued and outstanding, March 31, 2016 and June 30, 2015	24,341	24,341
Additional paid-in capital	41,268,207	38,138,754
Accumulated deficit	(40,173,970)	(29,109,288)
Total stockholders' equity	1,118,578	9,053,807
Total Liabilities, Series A Convertible Preferred Stock and Stockholders' Equity	$ 8,790,850	$ 11,263,202

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Jun. 30, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	24,338,219	24,338,219
Common stock, shares outstanding	24,338,219	24,338,219
Series A Convertible Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Redemption Price Per Share	$ 1.95	$ 1.95
Temporary Equity, Shares Authorized	15,000,000	15,000,000
Temporary Equity, Shares Issued	2,769,422	0
Temporary Equity, Shares Outstanding	2,769,422	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Research and development
Compensation and benefits	$ 1,180,350	$ 628,252	$ 3,187,751	$ 1,306,806
Consultants and outside costs	265,470	166,472	869,750	425,891
Material manufacturing costs	461,599	296,385	1,837,110	871,308
Facilities and other costs	402,770	199,686	907,721	365,511
Research and development	2,310,189	1,290,795	6,802,332	2,969,516
General and administrative
Consulting fees	0	33,000	0	349,633
Compensation and benefits	907,626	780,500	3,025,476	2,828,032
Professional fees	106,791	72,270	344,964	362,339
Investor relations	88,138	36,602	202,458	468,047
General and administrative	302,731	87,033	706,380	626,777
General and Administrative	1,405,286	1,009,405	4,279,278	4,634,828
Total operating expenses	3,715,475	2,300,200	11,081,610	7,604,344
Loss from operations	(3,715,475)	(2,300,200)	(11,081,610)	(7,604,344)
Other income (expense)
Interest income	1	1,093	965	4,062
Interest expense	(1,143)	(2,086)	(4,135)	(4,885)
Derivative gains (losses)	5,782	(871,447)	20,098	(717,733)
Total other income (expense)	4,640	(872,440)	16,928	(718,556)
Net loss	(3,710,835)	(3,172,640)	(11,064,682)	(8,322,900)
Cumulative Preferred Stock dividend	(61,279)	0	(61,279)	0
Net loss attributable to common stock	$ (3,772,114)	$ (3,172,640)	$ (11,125,961)	$ (8,322,900)
Net loss per common share - basic and diluted	$ (0.15)	$ (0.14)	$ (0.46)	$ (0.42)
Weighted average number of common shares outstanding - basic and diluted	24,338,219	22,542,821	24,338,219	19,840,425

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Jun. 30, 2014	$ 6,406,731	$ 18,092	$ 24,135,563	$ (17,746,924)
Balance (in shares) at Jun. 30, 2014		18,091,792
Stock-based compensation	2,846,828	$ 0	2,846,828	0
Issuance of common stock for services	368,419	$ 207	368,212	0
Issuance of common stock for services (in shares)		205,506
Fair value of warrants issued	6,026,070	$ 0	6,026,070	0
Issuance of common stock, net of issuance costs of $3,144,479	4,768,123	$ 6,042	4,762,081	0
Issuance of common stock, net of issuance costs of $3,144,479 (in shares)		6,040,921
Net loss	(11,362,364)	$ 0	0	(11,362,364)
Balance at Jun. 30, 2015	9,053,807	$ 24,341	38,138,754	(29,109,288)
Balance (in shares) at Jun. 30, 2015		24,338,219
Stock-based compensation	2,877,628	$ 0	2,877,628	0
Fair value of warrants issued	313,104	0	313,104	0
Dividends on Series A Preferred Stock	(61,279)	0	(61,279)	0
Net loss	(11,064,682)	0	0	(11,064,682)
Balance at Mar. 31, 2016	$ 1,118,578	$ 24,341	$ 41,268,207	$ (40,173,970)
Balance (in shares) at Mar. 31, 2016		24,338,219

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Jun. 30, 2015 USD ($)
Common Stock [Member]
Payments of stock issuance costs	$ 3,144,479

XML 18 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (11,064,682)	$ (8,322,900)
Amortization of intangible asset	5,469	3,432
Depreciation expense	476,941	91,021
Stock-based compensation expense	2,877,628	1,864,226
Stock issued for services	0	298,418
Derivative (gains) losses	(20,098)	717,733
Warrant expense	62,941	84,558
Forgiveness of accounts payable and accrued expenses - related party	0	132,339
Changes in operating assets and liabilities:
(Decrease) increase in other assets	(93,767)	105,577
Increase in accounts payable and accrued expenses	448,345	380,727
Decrease in accounts payable and accrued expenses - related party	0	(529,394)
Increase in interest payable	1,500	1,500
(Decrease) increase in deferred lease liability	(30,868)	57,017
Net Cash Used In Operating Activities	(7,336,591)	(5,115,746)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(1,774,413)	(874,960)
Acquisition of intangibles	0	(55,000)
Return of security deposit	187,500	0
Decrease (increase) in restricted cash	450,167	(450,055)
Net Cash Used In Investing Activities	(1,136,746)	(1,380,015)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on lease payable	(70,033)	(45,019)
Proceeds from issuance of equity financing	0	9,761,070
Proceeds from issuance of preferred stock	5,347,615	0
Payment of placement agent compensation and issuance costs	(336,929)	(930,106)
Net Cash Provided by Financing Activities	4,940,653	8,785,945
Net (decrease) increase in cash	(3,532,684)	2,290,184
Cash - Beginning of Period	5,278,706	5,934,534
Cash - End of Period	1,746,022	8,224,718
Cash Paid During the Period for:
Taxes	0	0
Interest	0	0
Non-Cash Transactions:
Warrant value recorded as issuance costs	250,163	1,671,618
Warrant derivative liability reclassified as equity	0	2,217,605
Series A Preferred Stock dividend paid in stock	61,279	0
Lease Payable
Non-Cash Transactions:
Fixed assets acquired	0	184,877
Tenant Improvements
Non-Cash Transactions:
Fixed assets acquired	0	511,616
Accounts payable and Accrued expenses
Non-Cash Transactions:
Fixed assets acquired	$ 312,229	$ 484,716

XML 19 R8.htm IDEA: XBRL DOCUMENT

Nature of Operations

9 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature Of Operation [Text Block]

Note 1 Nature of Operations

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Risks and Uncertainties

Restricted Cash

Research and Development Costs

Fair Value of Financial Instruments

Level 1: Quoted prices for identical assets and liabilities in active markets;

Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Balance as of June 30, 2015	$	(31,777)
Total unrealized gains (losses):
Included in earnings		20,098
Balance as of March 31, 2016	$	(11,679)

Recent Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Mar. 31, 2016

Going Concern [Abstract]

Going Concern Disclosure [Text Block]

Note 3 Going Concern

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fixed Assets

9 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Note 4 Fixed Assets

The following is a summary of fixed assets and accumulated depreciation:

	Useful
	Life	March 31, 2016		June 30, 2015
Furniture and fixtures	5 - 7 years	$	62,730	$	55,330
Lab equipment	3 - 15 years		3,378,355		889,671
Lab equipment (not yet placed in service)	3 - 15 years		113,965		1,371,441
Leasehold improvements	3 - 7 years		3,191,792		29,296
Construction in process	-		-		2,315,803
			6,746,842		4,661,541
Less: accumulated depreciation and amortization			(612,229)		(136,629)
		$	6,134,613	$	4,524,912

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Mar. 31, 2016

Note 5 Related Party Transactions

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

9 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note 6 Convertible Notes Payable

XML 25 R14.htm IDEA: XBRL DOCUMENT

Series A Convertible Preferred Stock

9 Months Ended

Mar. 31, 2016

Equity [Abstract]

Series A Convertible Preferred Stock [Text Block]

Note 7 Series A Convertible Preferred Stock

On March 31, 2016, the Company declared and issued 27,236 shares of Series A Stock as dividends on the current outstanding shares of Series A Stock.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

9 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

Note 8 Shareholders’ Equity

The Company has not declared or paid any dividends or returned any capital to common stock shareholders as of March 31, 2016.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Based Compensation [Text Block]

Note 9 Stock-Based Compensation

Options - AntriaBio adopted individual stock option plans in January 2013 for four officers and/or directors of the Company. The stock option plans granted 1,500,000 option shares with an exercise price of $4.50 per share. Options to purchase 819,445 shares vested immediately, options to purchase 541,667 shares vest monthly over 3 years and 138,888 shares vest on May 31, 2013. In June 2013, AntriaBio adopted individual stock option plans for two consultants of the Company. The stock option plans granted 8,334 shares with an exercise price of $4.50 per share and had fully vested as of June 30, 2015.

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2016 using the following assumptions:

Expected volatility	100	%
Risk free interest rate	1.91	%
Expected term (years)	7
Dividend yield	0	%

Stock option activity is as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Options		Exercise Price		Expected Life
Outstanding, June 30, 2014		4,343,334	$	3.61		5.6
Granted		4,572,000	$	2.02
Forfeited		(212,916)	$	3.57
Outstanding, June 30, 2015		8,702,418	$	2.78		7.1
Granted		50,000	$	1.40
Forfeited		(35,000)	$	1.75
Outstanding, March 31, 2016		8,717,418	$	2.77		6.4

Exercisable at March 31, 2016		4,041,063	$	3.27		5.0

Warrants- AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding, June 30, 2014		11,099,739	$	2.21		3.6
Warrants issued in private placement		6,040,921	$	2.50
Warrants issued to placement agent		1,824,489	$	2.50
Warrants issued for investor relations		111,000	$	1.63
Warrants cancelled		(59,758)	$	2.92
Outstanding, June 30, 2015		19,016,391	$	2.33		3.0
Warrants issued for investor relations		87,000	$	1.70
Warrants issued to placement agent		271,990	$	2.39
Warrants cancelled		(30,000)	$	3.44
Outstanding, March 31, 2016		19,345,381	$	2.32		2.3

Expected volatility	82% - 124	%
Risk free interest rate	0.56% - 2.21	%
Warrant term (years)	1 - 7.5
Dividend yield	0	%

Expected volatility	90% - 91	%
Risk free interest rate	1.89% - 1.98	%
Warrant term (years)	7
Dividend yield	0	%

Expected volatility	90	%
Risk free interest rate	1.71	%
Warrant term (years)	7
Dividend yield	0	%

XML 28 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 10 Income Taxes

In the nine months ended March 31, 2016, the Company did not record any income tax provision due to expected future losses and full valuation allowance on its deferred tax assets.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 11 Commitments and Contingencies

As of March 31, 2016, the minimum rental commitment under the lease is as follows:

Year Ending June 30,
2016 (remaining)		91,208
2017		370,252
2018		381,360
2019		392,855
2020		335,747
	$	1,571,422

As of March 31, 2016, minimum rental commitment under the lease is as follows:

Year Ending June 30,
2016 (remaining)	$	24,223
2017		24,223
Total rental commitments		48,446
Less: Interest payments		(1,500)
Total lease payable		46,946
Lease payable, current portion		46,946
Lease payable, less current portion	$	-

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Basis Of Accounting, Policy [Policy Text Block]

Basis of Presentation

Use Of Estimates, Policy [Policy Text Block]

Use of Estimates

Risks and Uncertainties [Policy Text Block]

Risks and Uncertainties

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Level 1: Quoted prices for identical assets and liabilities in active markets;

Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Balance as of June 30, 2015	$	(31,777)
Total unrealized gains (losses):
Included in earnings		20,098
Balance as of March 31, 2016	$	(11,679)

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy:

Balance as of June 30, 2015	$	(31,777)
Total unrealized gains (losses):
Included in earnings		20,098
Balance as of March 31, 2016	$	(11,679)

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fixed Assets (Tables)

9 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

The following is a summary of fixed assets and accumulated depreciation:

	Useful
	Life	March 31, 2016		June 30, 2015
Furniture and fixtures	5 - 7 years	$	62,730	$	55,330
Lab equipment	3 - 15 years		3,378,355		889,671
Lab equipment (not yet placed in service)	3 - 15 years		113,965		1,371,441
Leasehold improvements	3 - 7 years		3,191,792		29,296
Construction in process	-		-		2,315,803
			6,746,842		4,661,541
Less: accumulated depreciation and amortization			(612,229)		(136,629)
		$	6,134,613	$	4,524,912

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2016 using the following assumptions:

Expected volatility	100	%
Risk free interest rate	1.91	%
Expected term (years)	7
Dividend yield	0	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Options		Exercise Price		Expected Life
Outstanding, June 30, 2014		4,343,334	$	3.61		5.6
Granted		4,572,000	$	2.02
Forfeited		(212,916)	$	3.57
Outstanding, June 30, 2015		8,702,418	$	2.78		7.1
Granted		50,000	$	1.40
Forfeited		(35,000)	$	1.75
Outstanding, March 31, 2016		8,717,418	$	2.77		6.4

Exercisable at March 31, 2016		4,041,063	$	3.27		5.0

Schedule Of Warrants Issued To Agents Activity [Table Text Block]

AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding, June 30, 2014		11,099,739	$	2.21		3.6
Warrants issued in private placement		6,040,921	$	2.50
Warrants issued to placement agent		1,824,489	$	2.50
Warrants issued for investor relations		111,000	$	1.63
Warrants cancelled		(59,758)	$	2.92
Outstanding, June 30, 2015		19,016,391	$	2.33		3.0
Warrants issued for investor relations		87,000	$	1.70
Warrants issued to placement agent		271,990	$	2.39
Warrants cancelled		(30,000)	$	3.44
Outstanding, March 31, 2016		19,345,381	$	2.32		2.3

Black Scholes Pricing Model

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

Significant assumptions were as follows:

Expected volatility	82% - 124	%
Risk free interest rate	0.56% - 2.21	%
Warrant term (years)	1 - 7.5
Dividend yield	0	%

Lattice Model One

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

The estimated fair value was derived using the lattice model with the following assumptions:

Expected volatility	90% - 91	%
Risk free interest rate	1.89% - 1.98	%
Warrant term (years)	7
Dividend yield	0	%

Lattice Model Two

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

The estimated fair value was derived using the lattice model with the following assumptions:

Expected volatility	90	%
Risk free interest rate	1.71	%
Warrant term (years)	7
Dividend yield	0	%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

As of March 31, 2016, the minimum rental commitment under the lease is as follows:

Year Ending June 30,
2016 (remaining)		91,208
2017		370,252
2018		381,360
2019		392,855
2020		335,747
	$	1,571,422

Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]

As of March 31, 2016, minimum rental commitment under the lease is as follows:

Year Ending June 30,
2016 (remaining)	$	24,223
2017		24,223
Total rental commitments		48,446
Less: Interest payments		(1,500)
Total lease payable		46,946
Lease payable, current portion		46,946
Lease payable, less current portion	$	-

XML 35 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details)	9 Months Ended
Summary of Significant Accounting Policies (Details)	Mar. 31, 2016 USD ($)
Summary of Significant Accounting Policies [Line Items]
Balance as of June 30, 2015	$ (31,777)
Total unrealized gains (losses):
Included in earnings	20,098
Balance as of March 31, 2016	$ (11,679)

XML 36 R25.htm IDEA: XBRL DOCUMENT

Going Concern (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Going Concern (Details Textual) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Going Concern [Line Items]
Net Loss	$ (3,710,835)	$ (3,172,640)	$ (11,064,682)	$ (8,322,900)	$ (11,362,364)
Net Cash Used In Operating Activities			(7,336,591)	$ (5,115,746)
Total Stockholders' Equity	1,118,578		1,118,578		9,053,807	$ 6,406,731
Accumulated deficit	(40,173,970)		(40,173,970)		$ (29,109,288)
Working Capital Deficit	$ 378,829		$ 378,829

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

Fixed Assets (Details) - USD ($)	9 Months Ended
Fixed Assets (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 6,746,842	$ 4,661,541
Less: accumulated depreciation and amortization	(612,229)	(136,629)
Property, Plant and Equipment, Net	6,134,613	4,524,912
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 62,730	55,330
Furniture and fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,378,355	889,671
Lab equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Lab equipment (not yet placed in service) [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 113,965	1,371,441
Lab equipment (not yet placed in service) [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment (not yet placed in service) [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,191,792	29,296
Leasehold improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 0	$ 2,315,803
Property, Plant and Equipment, Useful Life	0 years

XML 38 R27.htm IDEA: XBRL DOCUMENT

Fixed Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Fixed Assets (Details Textual) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 256,404	$ 33,113	$ 476,941	$ 91,021

XML 39 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Mar. 31, 2015	Mar. 31, 2015
Related Party Transaction [Line Items]
Consulting expenses	$ 33,000	$ 99,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Convertible Notes Payable (Details Textual) - USD ($)	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2016	Jun. 30, 2015	Dec. 31, 2013
Convertible Notes Payable
Convertible Notes Payable [Line Items]
Debt instrument, interest rate, stated percentage			8.00%
Debt instrument, convertible, conversion price		$ 1.50
Debt conversion, converted instrument, amount	$ 4,275,172	$ 3,032,500
Beneficial conversion feature recorded as a debt discount		653,000
Debt instrument convertible number of common stock	3,111,126
Amortization of Debt Discount (Premium)		$ 653,000
Debt Instrument, Face Amount			$ 60,000	$ 60,000
2013 Notes
Convertible Notes Payable [Line Items]
Qualified financing	$ 2,703,000				$ 2,703,000
Debt instrument, interest rate, stated percentage					8.00%
Marketable securities, equity securities, current, total					$ 3,000,000
Common stock convertible conversion price					$ 1.26
Investment option convertible conversion price					1.26
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.89
Debt instrument convertible number of common stock	2,186,838

XML 41 R30.htm IDEA: XBRL DOCUMENT

Series A Convertible Preferred Stock (Details Textual) - USD ($)				1 Months Ended	3 Months Ended
	Apr. 12, 2016	Dec. 10, 2015	Dec. 07, 2015	Mar. 31, 2016	Mar. 31, 2016	Mar. 02, 2016	Jun. 30, 2015
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Shares Authorized				5,000,000	5,000,000		5,000,000
Preferred Stock Shares Issued				0	0		0
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Shares Authorized			15,000,000
Preferred Stock, Conversion Basis			The Series A Stock has a conversion feature at the option of the holder that can be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also have a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Company’s listing to NASDAQ Stockmarket or the NYSE MKT and the Company’s common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stock’s conversion price is subject to weighted average anti-dilution protection, as defined, and is subject to adjustments for stock splits, dividends, and similar events.
Preferred Stock, Dividend Rate, Percentage			6.00%
Preferred Stock, Redemption Price Per Share		$ 1.95				$ 1.95
Preferred Stock Shares Issued		1,025,699				1,716,487
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 1,803,548		$ 2,956,975
Preferred Stock, Liquidation Preference Per Share				$ 1.95	$ 1.95
Debt Instrument, Convertible, Conversion Price			$ 1.95
Preferred Stock, Accretion of Redemption Discount					$ 8,169
Dividends Preferred Stock, Shares				27,236
Series A Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Redemption Price Per Share	$ 1.95
Preferred Stock Shares Issued	512,820
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,000,000
Series A Convertible Preferred Stock [Member] \| Warrant [Member]
Series A Convertible Preferred Stock [Line Items]
Payments of Debt Issuance Costs		90,852		$ 159,311
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Series A Convertible Preferred Stock [Line Items]
Payments of Debt Issuance Costs		$ 105,715		$ 231,214

XML 42 R31.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
Shareholders' Equity (Details Textual) - USD ($)	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2014
Class of Stock [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued	$ 313,104	$ 6,026,070
Compensation For Services [Member]
Class of Stock [Line Items]
Common Stock To Be Issued			500,000
Warrant
Class of Stock [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		$ 2,072,911
Investor Relations
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other		166,668
Stock Issued During Period, Value, Other		$ 296,669
Private Placement
Class of Stock [Line Items]
Stock issued during period, shares, new issues		6,040,921
Proceeds from issuance of private placement		$ 10,100,000
Payments of stock issuance costs		$ 1,071,568
Class of warrant or right of warrants or rights expiring period		36 months
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.50
Stock Issued During Period, Shares, Issued for Services		37,838
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 70,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details)	9 Months Ended
Stock-Based Compensation (Details)	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%
Risk free interest rate	1.91%
Expected term (years)	7 years
Dividend yield	0.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 1) - Stock Option - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2014
Number of Options
Outstanding	8,702,418	4,343,334
Granted	50,000	4,572,000
Forfeited	(35,000)	(212,916)
Outstanding	8,717,418	8,702,418	4,343,334
Exercisable	4,041,063
Weighted Average Exercise Price
Outstanding	$ 2.78	$ 3.61
Granted	1.40	2.02
Forfeited	1.75	3.57
Outstanding	2.77	$ 2.78	$ 3.61
Exercisable	$ 3.27
Weighted Average Remaining Expected Life
Outstanding	6 years 4 months 24 days	7 years 1 month 6 days	5 years 7 months 6 days
Exercisable	5 years

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 2) - Warrant - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2014
Number of Warrants - Outstanding	19,016,391	11,099,739
Number of Warrants - Warrants issued in private placement		6,040,921
Number of Warrants - Warrants issued to placement agent	271,990	1,824,489
Number of Warrants - Warrants issued for investor relations	87,000	111,000
Number of Warrants - Warrants cancelled	(30,000)	(59,758)
Number of Warrants - Outstanding	19,345,381	19,016,391	11,099,739
Weighted Average Exercise Price - Outstanding	$ 2.33	$ 2.21
Weighted Average Exercise Price - Warrants issued in private placement		2.50
Weighted Average Exercise Price - Warrants issued to placement agent	2.39	2.50
Weighted Average Exercise Price - Warrants issued for investor relations	1.70	1.63
Weighted Average Exercise Price - Warrants cancelled	3.44	2.92
Weighted Average Exercise Price - Outstanding	$ 2.32	$ 2.33	$ 2.21
Weighted Average Remaining Contractual Life - Outstanding	2 years 3 months 18 days	3 years	3 years 7 months 6 days

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 3)	9 Months Ended
Stock-Based Compensation (Details 3)	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%
Risk free interest rate	1.91%
Warrant term (years)	7 years
Dividend yield	0.00%
Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Minimum \| Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	82.00%
Risk free interest rate	0.56%
Warrant term (years)	1 year
Maximum \| Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	124.00%
Risk free interest rate	2.21%
Warrant term (years)	7 years 6 months

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 4)	9 Months Ended
Stock-Based Compensation (Details 4)	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%
Risk free interest rate	1.91%
Warrant term (years)	7 years
Dividend yield	0.00%
Lattice Model One \| Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term (years)	7 years
Dividend yield	0.00%
Lattice Model One \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.89%
Lattice Model One \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	91.00%
Risk free interest rate	1.98%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details 5)	9 Months Ended
Stock-Based Compensation (Details 5)	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%
Risk free interest rate	1.91%
Warrant term (years)	7 years
Dividend yield	0.00%
Lattice Model Two \| Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.71%
Warrant term (years)	7 years
Dividend yield	0.00%

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Textual) - USD ($)	1 Months Ended				3 Months Ended	9 Months Ended		12 Months Ended
Stock-Based Compensation (Details Textual) - USD ($)	Feb. 23, 2015	Mar. 26, 2014	May. 31, 2013	Jan. 31, 2013	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Apr. 06, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation						$ 2,877,628	$ 1,864,226
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options					$ 8,599,608	$ 8,599,608
Class of warrant or right, number of securities called by warrants or rights					105,000	105,000
Fair value of warrants						$ 11,679		$ 31,777
Class of warrant exercisable warrants or rights					6,000	6,000
Adjustments to Additional Paid in Capital, Warrant Issued						$ 313,104		$ 6,026,070
Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights	58,914
Adjustments to Additional Paid in Capital, Warrant Issued	$ 92,111
Lattice Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value					$ 172,809	$ 172,809			$ 309,121
Lattice Model One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					1,418,373	1,418,373
Warrant derivative liability					$ 1,498,809	$ 1,498,809
Lattice Model Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights							99,650
Warrant derivative liability							$ 172,809
2014 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized		3,750,000
Two Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross								8,334
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price								$ 4.50
Employees and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			138,888
Employees and Directors \| General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation					613,710	1,959,736
Employees and Directors \| Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation					$ 297,925	$ 917,892
Employees and Directors \| 2014 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross						4,162,000
Share based compensation arrangement by share based payment award options shares purchased vested monthly term	4 years
Employees and Directors \| 2014 Stock and Incentive Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price	$ 1.40	$ 1.29
Employees and Directors \| 2014 Stock and Incentive Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 3.44
Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					9,000	9,000
Class of warrant exercisable warrants or rights					18,000	18,000
Warrants Not Settleable in Cash, Fair Value Disclosure					$ 11,407	$ 11,407
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross						50,000		4,572,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price						$ 1.40		$ 2.02
Employee Stock Option \| Employees and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross				1,500,000		3,295,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price				$ 4.50
Share-based compensation arrangement by share-based payment award, number of shares authorized	6,850,000
Employee Stock Option \| Employees and Directors \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price	$ 2.06
Share based compensation arrangement by share based payment award options shares purchased vested immediately				819,445
Share based compensation arrangement by share based payment award options shares purchased vested monthly				541,667
Share based compensation arrangement by share based payment award options shares purchased vested monthly term				3 years
Additional Paid-in Capital and Professional Fee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value					$ 80,677	$ 80,677
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					99,650	99,650
Adjustments to Additional Paid in Capital, Warrant Issued								$ 2,072,911
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants cancelled In Period						30,000		59,758
Warrant \| Lattice Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					1,518,387	1,518,387
Warrant \| Additional Paid-in Capital and Professional Fee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value					$ 9,006	$ 9,006
Warrant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					9,000	9,000		6,040,921
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.38	$ 1.38		$ 2.50
Warrant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					18,000	18,000		1,824,489
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.34	$ 1.34		$ 2.50
Warrant Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					60,000	60,000		105,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.85	$ 1.85		$ 1.65
Warrant Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price						$ 2.39
Class of warrant or right, number of securities called by warrants or rights					271,990	271,990		6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 1.38
Warrant Twelve
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants						$ 17,412
Class of warrant exercisable warrants or rights					271,990	271,990
Warrant Thirteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants						$ 34,122
Warrant Fourteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of warrants					$ 250,163
Warrant Fifteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					66,667	66,667
Adjustments to Additional Paid in Capital, Warrant Issued						$ 50,365
Warrant Sixteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					4,968,482	4,968,482
Warrants to purchase common stock value					$ 3,527,816	$ 3,527,816
Adjustments to Additional Paid in Capital, Warrant Issued						$ 2,597,932
Warrant Seventeen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					1,072,439	1,072,439
Class of warrant exercisable warrants or rights					1,477,287	1,477,287
Warrants to purchase common stock value					$ 1,009,433	$ 1,009,433
Adjustments to Additional Paid in Capital, Warrant Issued						$ 595,184
Warrant Eighteen \| Lattice Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights					1,418,373	1,418,373
Warrant derivative liability					$ 1,498,809	$ 1,498,809
Warrant Eighteen \| Derivative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value	$ 2,217,605								$ 124,434
Warrant Ninteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant exercisable warrants or rights					347,202	347,202			247,552

XML 50 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	Mar. 31, 2016 USD ($)
Operating Leased Assets [Line Items]
2016 (remaining)	$ 91,208
2017	370,252
2018	381,360
2019	392,855
2020	335,747
Operating Leases, Future Minimum Payments Due	$ 1,571,422

XML 51 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details 1) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Commitments And Contingencies [Line Items]
2016 (remaining)	$ 24,223
2017	24,223
Total rental commitments	48,446
Less: Interest payments	(1,500)
Total lease payable	46,946
Lease payable, current portion	46,946	$ 93,852
Lease payable, less current portion	$ 0	$ 23,127

XML 52 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual)	1 Months Ended
Commitments and Contingencies (Details Textual)	May. 31, 2014 USD ($) ft²	Mar. 31, 2016 USD ($)	Sep. 30, 2014 USD ($)
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense	$ 28,939
Payments Of Monthly Lease Adjusted Annually Percentage	3.00%
Adjusted Triple Net Expense Of Lease Payments	$ 34,381
Area of Land \| ft²	27,000
Security Deposit	$ 750,000
Capital Lease Obligations		$ 46,946
Proceeds from Other Deposits	$ 187,500
Capital Lease Obligations
Commitments And Contingencies [Line Items]
Capital Lease Obligations			$ 8,075

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 153 226 1 false 48 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.fitsmystyle.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.fitsmystyle.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.fitsmystyle.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.fitsmystyle.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.fitsmystyle.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 106 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.fitsmystyle.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 107 - Statement - Consolidated Statements of Cash Flows Sheet http://www.fitsmystyle.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 108 - Disclosure - Nature of Operations Sheet http://www.fitsmystyle.com/role/NatureOfOperations Nature of Operations Notes 8 false false R9.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 110 - Disclosure - Going Concern Sheet http://www.fitsmystyle.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 111 - Disclosure - Fixed Assets Sheet http://www.fitsmystyle.com/role/FixedAssets Fixed Assets Notes 11 false false R12.htm 112 - Disclosure - Related Party Transactions Sheet http://www.fitsmystyle.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 113 - Disclosure - Convertible Notes Payable Notes http://www.fitsmystyle.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 13 false false R14.htm 114 - Disclosure - Series A Convertible Preferred Stock Sheet http://www.fitsmystyle.com/role/SeriesConvertiblePreferredStock Series A Convertible Preferred Stock Notes 14 false false R15.htm 115 - Disclosure - Shareholders' Equity Sheet http://www.fitsmystyle.com/role/ShareholdersEquity Shareholders' Equity Notes 15 false false R16.htm 116 - Disclosure - Stock-Based Compensation Sheet http://www.fitsmystyle.com/role/StockbasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 117 - Disclosure - Income Taxes Sheet http://www.fitsmystyle.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 118 - Disclosure - Commitments and Contingencies Sheet http://www.fitsmystyle.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 120 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 121 - Disclosure - Fixed Assets (Tables) Sheet http://www.fitsmystyle.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://www.fitsmystyle.com/role/FixedAssets 21 false false R22.htm 122 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.fitsmystyle.com/role/StockbasedCompensation 22 false false R23.htm 123 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.fitsmystyle.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.fitsmystyle.com/role/CommitmentsAndContingencies 23 false false R24.htm 124 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.fitsmystyle.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 125 - Disclosure - Going Concern (Details Textual) Sheet http://www.fitsmystyle.com/role/GoingConcernDetailsTextual Going Concern (Details Textual) Details http://www.fitsmystyle.com/role/GoingConcern 25 false false R26.htm 126 - Disclosure - Fixed Assets (Details) Sheet http://www.fitsmystyle.com/role/FixedAssetsDetails Fixed Assets (Details) Details http://www.fitsmystyle.com/role/FixedAssetsTables 26 false false R27.htm 127 - Disclosure - Fixed Assets (Details Textual) Sheet http://www.fitsmystyle.com/role/FixedAssetsDetailsTextual Fixed Assets (Details Textual) Details http://www.fitsmystyle.com/role/FixedAssetsTables 27 false false R28.htm 128 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.fitsmystyle.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.fitsmystyle.com/role/RelatedPartyTransactions 28 false false R29.htm 129 - Disclosure - Convertible Notes Payable (Details Textual) Notes http://www.fitsmystyle.com/role/ConvertibleNotesPayableDetailsTextual Convertible Notes Payable (Details Textual) Details http://www.fitsmystyle.com/role/ConvertibleNotesPayable 29 false false R30.htm 130 - Disclosure - Series A Convertible Preferred Stock (Details Textual) Sheet http://www.fitsmystyle.com/role/SeriesConvertiblePreferredStockDetailsTextual Series A Convertible Preferred Stock (Details Textual) Details http://www.fitsmystyle.com/role/SeriesConvertiblePreferredStock 30 false false R31.htm 131 - Disclosure - Shareholders' Equity (Details Textual) Sheet http://www.fitsmystyle.com/role/ShareholdersEquityDetailsTextual Shareholders' Equity (Details Textual) Details http://www.fitsmystyle.com/role/ShareholdersEquity 31 false false R32.htm 132 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetails Stock-Based Compensation (Details) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 32 false false R33.htm 133 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetails1 Stock-Based Compensation (Details 1) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 33 false false R34.htm 134 - Disclosure - Stock-Based Compensation (Details 2) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetails2 Stock-Based Compensation (Details 2) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 34 false false R35.htm 135 - Disclosure - Stock-Based Compensation (Details 3) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetails3 Stock-Based Compensation (Details 3) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 35 false false R36.htm 136 - Disclosure - Stock-Based Compensation (Details 4) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetails4 Stock-Based Compensation (Details 4) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 36 false false R37.htm 137 - Disclosure - Stock-Based Compensation (Details 5) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetails5 Stock-Based Compensation (Details 5) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 37 false false R38.htm 138 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://www.fitsmystyle.com/role/StockbasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) Details http://www.fitsmystyle.com/role/StockbasedCompensationTables 38 false false R39.htm 139 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.fitsmystyle.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.fitsmystyle.com/role/CommitmentsAndContingenciesTables 39 false false R40.htm 140 - Disclosure - Commitments and Contingencies (Details 1) Sheet http://www.fitsmystyle.com/role/CommitmentsAndContingenciesDetails1 Commitments and Contingencies (Details 1) Details http://www.fitsmystyle.com/role/CommitmentsAndContingenciesTables 40 false false R41.htm 141 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.fitsmystyle.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.fitsmystyle.com/role/CommitmentsAndContingenciesTables 41 false false All Reports Book All Reports antb-20160331.xml antb-20160331.xsd antb-20160331_cal.xml antb-20160331_def.xml antb-20160331_lab.xml antb-20160331_pre.xml true true ZIP 59 0001144204-16-102291-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-102291-xbrl.zip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end